# INNOVATE Corp.: Form 10-Q for the period ended Sep 30, 2025

- Company: [INNOVATE Corp.](/companies/vate.md) (CIK 1006837)
- Form: 10-Q
- Filed: 2025-11-12
- Accepted by EDGAR: Nov 12, 2025, 16:12 ET
- Period: 2025-09-30
- Accession: 0001006837-25-000127
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000127/vate-20250930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000127/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-07-01 to 2025-09-30 | $347.1m | us-gaap:Revenues |
| Revenue | 9 months, 2025-01-01 to 2025-09-30 | $863.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2025-07-01 to 2025-09-30 | $297.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2025-01-01 to 2025-09-30 | $722.5m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2025-07-01 to 2025-09-30 | $49.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2025-01-01 to 2025-09-30 | $140.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2025-07-01 to 2025-09-30 | $39.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2025-01-01 to 2025-09-30 | $112.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-07-01 to 2025-09-30 | $6.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2025-01-01 to 2025-09-30 | $14.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-07-01 to 2025-09-30 | $23.4m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2025-01-01 to 2025-09-30 | $65.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2025-07-01 to 2025-09-30 | −$7.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2025-01-01 to 2025-09-30 | $4.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-07-01 to 2025-09-30 | −$8.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2025-01-01 to 2025-09-30 | −$53.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-07-01 to 2025-09-30 | −$0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2025-01-01 to 2025-09-30 | −$4.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-07-01 to 2025-09-30 | −$0.71 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2025-01-01 to 2025-09-30 | −$4.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-07-01 to 2025-09-30 | 13,264,799 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2025-01-01 to 2025-09-30 | 13,176,043 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2025-01-01 to 2025-09-30 | $45.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2025-01-01 to 2025-09-30 | $500.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2025-01-01 to 2025-09-30 | $1.5m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2025-09-30 | $35.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-09-30 | $420.6m | us-gaap:AssetsCurrent |
| Total assets | at 2025-09-30 | $913.2m | us-gaap:Assets |
| Current liabilities | at 2025-09-30 | $974.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-09-30 | $1.12bn | us-gaap:Liabilities |
| Current portion of debt | at 2025-09-30 | $571.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2025-09-30 | −$233.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 133,528 characters.

You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated annual audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025 (the "2024 Annual Report"), and the unaudited condensed consolidated financial statements and related notes to this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section in our 2024 Annual Report as well as the section below entitled "Special Note Regarding Forward-Looking Statements" for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Unless the context otherwise requires, in this Quarterly Report on Form 10-Q, "INNOVATE" means INNOVATE Corp. and the "Company," "we" and "our" mean INNOVATE together with its consolidated subsidiaries. "U.S. GAAP" means accounting principles accepted in the United States of America.

### Our Business and Our Operations

We are a diversified holding company with principal operations conducted through three operating platforms or reportable segments: Infrastructure ("DBMG"), Life Sciences ("Pansend"), and Spectrum, plus our Other segment, which includes businesses that do not meet the separately reportable segment thresholds.

For additional information on our business, refer to Note 1. Organization and Business to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Cyclical Patterns

Our segments' operations can be highly cyclical. Our volume of business in our Infrastructure segment may be adversely affected by declines or delays in projects, which may vary by geographic region. Project schedules, particularly in connection with large, complex, and longer-term projects can also create fluctuations in the services provided, which may adversely affect us in any given period.

For example, in connection with larger, more complicated projects, the timing of obtaining permits and other approvals may be delayed, and we may need to maintain a portion of our workforce and equipment in an underutilized capacity to ensure we are strategically positioned to deliver on such projects when they move forward.

Examples of other items that may cause our results or demand for our services to fluctuate materially from quarter to quarter include: weather or project site conditions; the spending patterns, including seasonal trends, and financial condition of our customers and their access to capital; our profit margins on projects performed during any particular period; rising interest rates and inflation; and regulatory, economic, political and market conditions on a regional, national or global scale.

Accordingly, our operating results in any particular period may not be indicative of the results that can be expected for any other period.

### Recent Developments

We continually evaluate strategic and business alternatives within our operating segments, which may include the following: operating, growing or acquiring additional assets or businesses related to current or historical operations; or winding down or selling our existing operations. In the longer term, we may evaluate opportunities to acquire assets or businesses unrelated to our current or historical operations. In the event we were to enter into a strategic transaction to sell any of our existing operations, our intention is to use available proceeds from such transaction to address our capital structure.

In 2025, as part of our strategic process, we engaged in several transactions that had or will have an effect on the results of operations and financial condition of our business and individual segments.

### Debt Obligations and Financing

During 2025, we have refinanced our debt, including at the subsidiary level. This financing helped us provide needed capital for our operations and the operations of our subsidiaries, and the refinancing of the debt, which, among other things, extended the maturities of the debt, allows us to continue to pursue our strategic plans.

#### Infrastructure

On May 20, 2025, DBMG entered into an Amended and Restated Credit agreement (the "DBMG Credit Agreement"), with the lenders which are party thereto from time to time (each a “Lender” and collectively the “Lenders”) and UMB BANK, N.A. ("UMB"). The DBMG Credit Agreement provides DBMG with senior secured debt financing in an amount up to $220.0 million in the aggregate, consisting of (i) a senior secured revolving credit facility (the “DBMG Revolving Facility”) in an aggregate amount of $135.0 million and (ii) a senior secured term loan facility in the amount of $85.0 million. The DBMG Credit Agreement also contains an accordion feature to increase the allowable size of the DBMG Revolving Facility by an additional $50.0 million. The DBMG Revolving Facility and term loan facility will mature on May 20, 2030. DBMG entered into the DBMG Credit Agreement to fully repay DBMG’s existing debt obligations and provide additional working capital capacity.

As of September 30, 2025, DBMG had a total outstanding balance of $20.0 million under its new revolving facility and the effective interest rate on DBMG's revolving loans was 7.28%. Interest on the new revolving facility is paid monthly, and the new revolving facility has an unused commitment fee of 0.50% per annum times the average daily unused availability under the line. As of September 30, 2025, the total outstanding balance of DBMG's term loans was $83.9 million. Principal payments and interest on DBMG's term loans are paid monthly, and the effective interest rate was 7.87% as of September 30, 2025. Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information, regarding the recent refinancing and indebtedness of our Infrastructure segment.

#### Life Sciences

On August 4, 2025, Lancer Capital, a related party, and R2 Technologies entered into an Amended and Restated Senior Secured Promissory Note, which was previously amended multiple times, and which, among other things, extended the maturity of the note to the earlier of August 1, 2026, or the occurrence of (i) a Change of Control (as defined in the amended note) or (ii) the sale of all or substantially all of the assets of R2 Technologies. The amended note has an interest rate of 12% and removed certain exit and default fees. Accrued and unpaid interest is capitalized monthly into the principal balance.

The total new initial principal amount of the amended note on August 4, 2025 was $43.5 million, which incorporated the $20.0 million principal amount of the note as previously amended effective January 31, 2024 (which was comprised of a principal amount of $17.4 million and unpaid accrued interest of $2.6 million), accrued interest of $7.0 million and $16.5 million in accrued exit fees which had been incurred from January 31, 2024 through August 4, 2025. In addition, a new 5% extension fee of $2.2 million was capitalized into the principal amount on August 4, 2025. The amended note had a principal balance of $46.5 million as of September 30, 2025.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on the note and its various amendments.

On February 20, 2025, Pansend closed on a $3.5 million convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend into shares of a new Series E Convertible Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date, as amended on July 23, 2025, of the earlier of July 31, 2026, or a change in control of R2 Technologies, as defined in the note. On June 9, 2025, Pansend closed on a $3.0 million convertible 13.0% note instrument with R2 Technologies, of which $2.5 million had been funded as of September 30, 2025. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend into shares of a new Series F Convertible Preferred Stock ("Series F") in R2 Technologies upon written notice to R2 Technologies and has a maturity date, as amended on July 23, 2025, of the earlier of July 31, 2026, or a change in control of R2 Technologies, as defined in the note. These notes and related intercompany interest are eliminated on consolidation. Subsequent to quarter end, in October and November 2025, an additional $0.5 million was funded. Refer to Note 15. Equity and Temporary Equity to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.

#### Spectrum

On August 4, 2025, Spectrum entered into a Tenth Omnibus Amendment to Secured Notes and Limited Consent to MSD Secured Note and Intercreditor Agreement with the note holders of Spectrum’s $69.7 million 8.50% and 11.45% Notes (the “Spectrum Notes”) to, among other things, extend the maturity of such notes from August 15, 2025 to September 30, 2026 (the “Spectrum Notes Extension”). Interest is capitalized and payable upon maturity of the notes. As a result of Spectrum Notes Extension, additional exit fees of $9.9 million were incurred. The total exit fees associated with the notes of $25.8 million is payable on the earlier of maturity or repayment of the principal, and is reflected within Accrued liabilities in the Condensed Consolidated Balance Sheet as of September 30, 2025.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our Spectrum debt.

#### Non-Operating Corporate

In August 2025, the Company closed on a series of indebtedness refinancing transactions that extended certain of INNOVATE's debt maturities. These refinancing transactions included: (i) the closings of an exchange offer and consent solicitation with respect to the Company’s senior secured notes; (ii) privately negotiated exchanges of certain of the Company’s convertible senior notes; (iii) amendment and extension of the Company’s 2020 Revolving Credit Agreement to September 15, 2026; and (iv) amendment and extension of the Company’s CGIC note to April 30, 2027, as well as the exchange of a portion of the Company’s preferred stock held by CGIC and accrued preferred stock dividends in exchange for increasing the principal amount of that note (the "Preferred Stock Exchange")

The Company issued $360.4 million aggregate principal amount of 10.50% 2027 Senior Secured Notes, at 100% of par, as consideration for the exchange of $328.1 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes. The new principal amounts also include fees payable to the lenders and amounts in lieu of interest payments that were due August 1, 2025. The 10.50% 2027 Senior Secured Notes mature on February 1, 2027 and accrue interest at a rate of 10.50% per year, payable semi-annually on February 1st and August 1st of each year. For the first interest period only, interest will be paid in kind. All subsequent interest payments are payable in cash.

The Company exchanged $48.7 million of aggregate principal amount of the 2026 Convertible Notes for $53.5 million aggregate principal amount of newly issued 9.5% Convertible Senior Secured Notes due 2027 (the “2027 Convertible Notes”). The new principal amounts also include fees payable to the lenders and amounts in lieu of interest payments that were due on August 1, 2025. The 2027 Convertible Notes mature on March 1, 2027 and interest on the 2027 Convertible Notes is paid semi-annually on February 1st and August 1st of each year. For the first interest period only, interest will be paid in kind. All subsequent interest payments are payable in cash.

The amended CGIC Note has a fixed interest rate of 16.0%, Interest on the amended CGIC Note will be paid on a monthly basis and in kind through August 31, 2026. All interest payments thereafter will be payable in cash. The additional principal amount incurred under the Preferred Stock Exchange was $9.6 million (reflective of the $9.1 million accrued value of the Series A-4 Preferred Stock and $0.5 million in accrued dividends on the Series A-3 and A-4 Preferred Stock). In addition, an extension fee and accrued interest of $2.4 million on the CGIC Note through July 31, 2025, were capitalized to the new principal amount of the CGIC Note, for a total new aggregate outstanding principal amount of $43.0 million. As of September 30, 2025, the total carrying amount related to the CGIC Note was $45.1 million, inclusive of $44.1 million of principal (including capitalized interest), and a net premium of $1.0 million.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our Non-Operating Corporate segment debt.

### Equity Method Investments

On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased from 45.9% prior to the transactions to 44.7% subsequent to the transactions. On a fully diluted basis, Pansend's ownership in MediBeacon decreased from 40.1% to 39.7%. Refer to Note 6. Investments, which is incorporated herein by reference, for additional information.

### Financial Presentation Background

In the below section within this Management’s Discussion and Analysis of Financial Condition and Results of Operations, we compare, pursuant to U.S. GAAP and SEC disclosure rules, the Company’s results of operations for the three and nine months ended September 30, 2025, as compared to the three and nine months ended September 30, 2024.

### Results of Operations

The following table summarizes our results of operations (in millions):

| Revenue | Three Months Ended September 30, 2025 | 2024 | Increase / (Decrease) | Nine Months Ended September 30, 2025 | 2024 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Infrastructure | $338.4 | $232.8 | $105.6 | $836.4 | $845.9 | $(9.5) |
| Life Sciences | 3.1 | 3.0 | 0.1 | 9.4 | 5.7 | 3.7 |
| Spectrum | 5.6 | 6.4 | (0.8) | 17.5 | 18.9 | (1.4) |
| Total revenue | $347.1 | $242.2 | $104.9 | $863.3 | $870.5 | $(7.2) |
| Income (loss) from operations |  |  |  |  |  |  |
| Infrastructure | $16.0 | $12.3 | $3.7 | $35.7 | $57.1 | $(21.4) |
| Life Sciences | (2.8) | (3.3) | 0.5 | (8.6) | (10.5) | 1.9 |
| Spectrum | (0.1) | (0.1) | — | (0.2) | 0.2 | (0.4) |
| Non-Operating Corporate | (7.0) | (3.0) | (4.0) | (12.5) | (9.3) | (3.2) |
| Total income from operations | $6.1 | $5.9 | $0.2 | $14.4 | $37.5 | $(23.1) |
| Interest expense | (23.4) | (21.2) | (2.2) | (65.0) | (54.9) | (10.1) |
| Loss from equity investees | — | — | — | (5.9) | (2.3) | (3.6) |
| Other income, net | 0.6 | 2.2 | (1.6) | 4.3 | 1.2 | 3.1 |
| Loss from operations before income taxes | $(16.7) | $(13.1) | $(3.6) | $(52.2) | $(18.5) | $(33.7) |
| Income tax benefit (expense) | 7.1 | (3.1) | 10.2 | (4.2) | (3.9) | (0.3) |
| Net loss | $(9.6) | $(16.2) | $6.6 | $(56.4) | $(22.4) | $(34.0) |
| Net loss attributable to non-controlling interests and redeemable non-controlling interests | 0.7 | 1.2 | (0.5) | 3.2 | 4.4 | (1.2) |
| Net loss attributable to INNOVATE Corp. | $(8.9) | $(15.0) | $6.1 | $(53.2) | $(18.0) | $(35.2) |
| Less: Preferred dividends | 0.5 | 0.3 | 0.2 | 3.0 | 0.9 | 2.1 |
| Net loss attributable to common stockholders and participating preferred stockholders | $(9.4) | $(15.3) | $5.9 | $(56.2) | $(18.9) | $(37.3) |

*Revenue*: Revenue for the three months ended September 30, 2025 increased $104.9 million to $347.1 million from $242.2 million for the three months ended September 30, 2024. The increase was driven primarily by our Infrastructure segment, which was partially offset by a decrease at our Spectrum segment. The increase at our Infrastructure segment was primarily driven by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business and a slight increase at Banker Steel, which had increased activity subsequent to the comparable period on certain large commercial construction projects. These increases were partially offset by the industrial maintenance and repair business due to increased activity in the comparable period on certain large commercial construction and industrial maintenance projects that have since been completed. The decrease at our Spectrum segment was primarily driven by the termination of certain customers in the current period and a downturn in the direct response advertising market.

Revenue for the nine months ended September 30, 2025, decreased $7.2 million to $863.3 million from $870.5 million for the nine months ended September 30, 2024. The decrease was primarily driven by our Infrastructure segment, and to a lesser extent our Spectrum segment, which was partially offset by an increase at our Life Sciences segment. The decrease at our Infrastructure segment was primarily driven by the timing and size of projects at Banker Steel, the industrial maintenance and repair business, and the construction modeling and detailing business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the prior year on certain large commercial construction projects that have since been completed or are nearing completion in the current period. These decreases were partially offset by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large commercial construction projects. The decrease at our Spectrum segment was primarily driven by the termination of certain customers in the current period and a downturn in the direct response advertising market, which was partially offset by the launch of new networks subsequent to the comparable period. The increase at our Life Sciences segment was attributable to R2 Technologies, primarily driven by an increase in Glacial Spa and Glacial fx unit sales outside North America, as well as an increases in consumable sales and Glacial fx and Glacial Rx unit sales in North America.

*Income from operations*: Income from operations for the three months ended September 30, 2025, increased $0.2 million to $6.1 million from $5.9 million for the three months ended September 30, 2024. The increase was primarily due to a net increase in gross profit of $1.5 million and an increase in other operating income of $0.8 million, which were mostly offset by a net increase in selling, general and administrative ("SG&A") expenses of $2.2 million. The net increase in gross profit was primarily driven by our Infrastructure segment due to timing and size of projects, which had increased activity subsequent to the comparable period on certain large commercial construction projects, which was partially offset by our Spectrum segment due to the termination of certain customers in the current period and a downturn in the direct response advertising market. The increase in other operating income was primarily driven by our Spectrum segment due to a favorable legal settlement in the current period and unrepeated lease termination settlement costs incurred in the comparable period. The increase in SG&A was primarily driven by our Non-Operating Corporate segment primarily due to the debt refinancing costs expensed in the current period and an increase in share-based compensation expense related to the vesting and issuance of equity awards to our Interim-CEO, which awards had not yet been vested or granted in the comparable period, which was partially offset by a decrease in other legal fees and a decrease in SG&A at our Infrastructure segment due to a decrease in compensation-related expenses and consulting fees, and to a lesser extent our Life Sciences segment due to a reduction in compensation-related expenses at Pansend.

Income from operations for the nine months ended September 30, 2025, decreased $23.1 million to $14.4 million from $37.5 million for the nine months ended September 30, 2024. The decrease was primarily due to a net decrease in gross profit of $21.6 million, and a net decrease in other operating income of $8.9 million, partially offset by a net decrease in SG&A expenses of $7.3 million. The net decrease in gross profit was primarily driven by our Infrastructure segment due to timing and size of projects that have since been completed or are nearing completion in the current period, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period and, to a lesser extent, our Spectrum segment primarily due to the termination of certain customers in the current period and a downturn in the direct response advertising market. The decrease in other operating income was primarily driven by our Infrastructure segment as a result of unrepeated gains on lease modifications and unrepeated gains on the sale of various properties in the comparable period, as well as various losses on the sale of properties and a loss on lease modification in the current period, which was partially offset by our Spectrum segment due to a favorable legal settlement in the current period and unrepeated lease termination settlement costs incurred in the comparable period. The decrease in SG&A, which was primarily driven by our Infrastructure segment primarily due to a decrease in compensation-related expenses primarily due to timing, and, to a lesser extent, decreases in consulting fees and travel expenses, and a decrease at our Life Sciences segment due to a reduction in compensation-related expenses at Pansend. The decreases in SG&A were partially offset by our Non-Operating Corporate segment primarily due to the debt refinancing costs expensed in the current period and an increase in share-based compensation expense related to the vesting and issuance of equity awards to our Interim-CEO, which awards had not yet been vested or granted in the comparable period, which were partially offset by a decrease in other legal fees.

*Interest expense*: Interest expense for the three months ended September 30, 2025, increased $2.2 million to $23.4 million from $21.2 million for the three months ended September 30, 2024. The increase in interest expense was primarily attributable to our Non-Operating Corporate segment, reflecting the impact of the indebtedness refinancing transactions completed during the current period. These transactions resulted in increased principal balances due to the capitalization of fees and interest, and certain increases in interest rates, leading to increased interest expense including amortization of fees. The increases were partially offset by our Life Sciences and Infrastructure segments. The decrease at our Life Sciences segment was primarily due to the refinancing of the note, which removed certain exit and default fees and decreased the stated interest rate, which was partially offset by the higher outstanding principal amount. The decrease at our Infrastructure segment was due to a net decrease in outstanding principal balances. Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on the indebtedness refinancing transactions.

Interest expense for the nine months ended September 30, 2025, increased $10.1 million to $65.0 million from $54.9 million for the nine months ended September 30, 2024. The increase in interest expense was primarily driven by our Life Sciences and Non-Operating Corporate segments, and to a lesser extent by our Spectrum segment. The increase at our Life Sciences segment was due to a higher outstanding principal amount resulting from the capitalization of unpaid interest and exit fees into the principal amount subsequent to the comparable period. Interest expense at our Non-Operating Corporate segment increased due to the indebtedness refinancing transactions completed during the current period, which resulted in increased principal balances due to the capitalization of fees and interest, and certain increases in interest rates, leading to increased interest expense including amortization of fees. The increase at our Spectrum segment was due to the refinancing transactions and increased fees subsequent to the comparable period. These increases in interest expense were slightly offset by a decrease at our Infrastructure segment due to a net decrease in outstanding principal balances. Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on the indebtedness refinancing transactions.

*Loss from equity investees:* Loss from equity investees for the nine months ended September 30, 2025, increased $3.6 million to $5.9 million from $2.3 million for the nine months ended September 30, 2024. The increase in loss was due to an increase in losses recognized from MediBeacon. During the nine months ended September 30, 2025, as a result of the first quarter equity transactions that occurred upon FDA approval of MediBeacon's TGFR, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. During the nine months ended September 30, 2024, Pansend's basis in MediBeacon had increased by $2.3 million due to the issuance of additional convertible note investments in the comparable period, resulting in Pansend recognizing $2.3 million of equity method losses that were previously unrecognized. As of both September 30, 2025 and 2024, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment. Refer to Note 6. Investments to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.

*Other income, net:* Other income, net for the three months ended September 30, 2025, decreased $1.6 million to $0.6 million from $2.2 million for the three months ended September 30, 2024. The decrease was primarily driven by an unrepeated $1.9 million gain on debt repurchase at our Non-Operating Corporate segment related to the partial repurchase of the 2026 Convertible Notes in the comparable period and a decrease in interest income at our Life Sciences and Non-Operating Corporate segments. These decreases were partially offset by a decrease in foreign currency translation losses from our Infrastructure segment and an increase in fair value gains on marketable securities at our Non-Operating Corporate segment.

Other income, net for the nine months ended September 30, 2025, increased $3.1 million to $4.3 million from $1.2 million for the nine months ended September 30, 2024. The increase was primarily driven by the $4.4 million step-up gain following MediBeacon's FDA approval in January 2025, and an increase in fair value gains on marketable securities at our Non-Operating Corporate segment. These increases were partially offset by a decrease in interest income at our Life Sciences and Non-Operating Corporate segments, an increase in foreign currency translation losses from our Infrastructure segment and a legal settlement expense at our Non-Operating Corporate segment in the current period. Net loss on repurchase or extinguishment of debt remained consistent as compared to the prior period; however, the net loss was comprised of a loss on extinguishment of debt of $0.3 million related to a refinancing at our Infrastructure segment during the nine months ended September 30, 2025, as compared to a $2.2 million loss on debt extinguishment at R2 Technologies in the comparable period, which was largely offset by a $1.9 million gain on debt repurchase at our Non-Operating Corporate segment related to the partial repurchase of the 2026 Convertible Notes in the comparable period.

*Income tax benefit (expense)*: Income tax benefit for the three months ended September 30, 2025, increased $10.2 million to a benefit of $7.1 million from an expense of $3.1 million for the three months ended September 30, 2024. Income tax expense for the nine months ended September 30, 2025, increased $0.3 million to $4.2 million from $3.9 million for the nine months ended September 30, 2024. The movement in tax benefit and expense were primarily driven by the impact of projected pre-tax results on the annual effective tax rate including the limitations on the utilization of net operating losses ("NOL") by INNOVATE's U.S. consolidated group as a result of the Internal Revenue Code Section 382 and the Tax Cuts and Jobs Act's 80 percent limitation on NOLs incurred after 2017.

The Organization for Economic Cooperation and Development ("OECD") has announced an Inclusive Framework on Base Erosion and Profit Shifting including a Pillar Two Model to provide for a 15% global minimum tax on the earnings of multinational corporations with consolidated revenue over €750 million. Many jurisdictions have enacted Pillar Two legislation that started to become effective in 2024. The OECD, and its member countries, continue to release new guidance and legislation on Pillar Two. Based on current enacted laws, Pillar Two is not expected to materially impact our effective tax rate or cash flows in the next year. We will continue to evaluate the impact on our financial position as new legislation or guidance is introduced which could change our current assessment.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted into law, introducing various changes to U.S. federal income tax provisions, including modifications to bonus depreciation, interest expense limitations, and the treatment of research and development expenditures. Under ASC 740, the effects of newly enacted tax legislation must be recognized in the period that includes the enactment date. We have evaluated the provisions of the OBBBA and their potential impact on the financial statements. Based on this preliminary assessment, we do not expect the OBBBA to have a material effect on the current or deferred income tax balances, effective tax rate, or overall financial position. We have included the effects of the legislation in our estimated annual effective tax rate for the three and nine months ended September 30, 2025 and will continue to monitor developments and assess the impact of the OBBBA as further guidance becomes available and as facts and circumstances evolve.

### Segment Results of Operations

In the Company's Condensed Consolidated Financial Statements, other operating (income) loss includes: (i) (gain) loss on sale or disposal of assets; (ii) lease termination costs and (gains) losses on lease modifications; (iii) asset impairment expense; and (iv) accretion of asset retirement obligations; as applicable. Each table summarizes the results of operations of our operating segments (in millions).

### Infrastructure Segment

|  | Three Months Ended September 30, 2025 | 2024 | Increase / (Decrease) | Nine Months Ended September 30, 2025 | 2024 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $338.4 | $232.8 | $105.6 | $836.4 | $845.9 | $(9.5) |
| Cost of revenue | 292.3 | 189.1 | 103.2 | 707.2 | 695.7 | 11.5 |
| Selling, general and administrative | 27.0 | 28.3 | (1.3) | 83.1 | 93.0 | (9.9) |
| Depreciation and amortization | 3.0 | 3.0 | — | 9.2 | 8.9 | 0.3 |
| Other operating loss (income) | 0.1 | 0.1 | — | 1.2 | (8.8) | 10.0 |
| Income from operations | $16.0 | $12.3 | $3.7 | $35.7 | $57.1 | $(21.4) |

*Revenue:* Revenue for the three months ended September 30, 2025 increased $105.6 million to $338.4 million from $232.8 million for the three months ended September 30, 2024. The increase was primarily driven by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business and a slight increase at Banker Steel, which had increased activity subsequent to the comparable period on certain large commercial construction projects as several projects progressed into more advanced phases of fabrication and erection during the current period. These increases were partially offset by the industrial maintenance and repair business due to increased activity in the comparable period on certain large commercial construction and industrial maintenance projects that have since been completed.

Revenue for the nine months ended September 30, 2025, decreased $9.5 million to $836.4 million from $845.9 million for the nine months ended September 30, 2024. The decrease was primarily driven by the timing and size of projects at Banker Steel, the industrial maintenance and repair business, and the construction modeling and detailing business, including the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable period, which also had increased activity in the prior year on certain large commercial construction projects that have since been completed or are nearing completion in the current period. These decreases were partially offset by the timing and size of projects at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large commercial construction projects.

*Cost of revenue*: Cost of revenue for the three months ended September 30, 2025 increased $103.2 million to $292.3 million from $189.1 million for the three months ended September 30, 2024. The increase was primarily driven by the increase in revenues at DBMG's commercial structural steel fabrication and erection business due to the increased activity subsequent to the comparable period on certain large commercial construction projects, which was partially offset by the industrial maintenance and repair business due to the decrease in revenue and decrease in project costs as they had increased activity in the prior year on certain large commercial construction and industrial maintenance projects that have since been completed.

Cost of revenue for the nine months ended September 30, 2025, increased $11.5 million to $707.2 million from $695.7 million for the nine months ended September 30, 2024. The increase was primarily driven by the increase in revenues at DBMG's commercial structural steel fabrication and erection business due to the increased activity subsequent to the comparable period on certain large commercial construction projects, which was partially offset by decreases in revenues at Banker Steel, the industrial maintenance and repair business and the construction modeling and detailing business from the timing of project activity on certain large commercial construction projects and decreases in costs as they were completed or are nearing completion in the current period.

*Selling, general and administrative: S*elling, general and administrative expense for the three months ended September 30, 2025 decreased $1.3 million to 27.0 million from $28.3 million for the three months ended September 30, 2024. The decrease was primarily driven by a decrease in compensation-related expenses and consulting fees.

*S*elling, general and administrative expense for the nine months ended September 30, 2025, decreased $9.9 million to $83.1 million from $93.0 million for the nine months ended September 30, 2024. The decrease was primarily driven by a decrease in compensation-related expenses primarily due to timing, and, to a lesser extent, decreases in consulting fees and travel expenses.

*Depreciation and amortization*: Depreciation and amortization for the nine months ended September 30, 2025 increased slightly by $0.3 million to $9.2 million from $8.9 million for the nine months ended September 30, 2024.

*Other operating loss (income)*: Other operating loss (income) for the nine months ended September 30, 2025, decreased by $10.0 million to a loss of $1.2 million from income of $8.8 million for the nine months ended September 30, 2024. The decrease was primarily driven by unrepeated gains on lease modifications and unrepeated gains on the sale of various properties in the comparable period, as well as various losses on the sale of properties and a loss on lease modification in the current period.

### Life Sciences Segment

|  | Three Months Ended September 30, 2025 | 2024 | Increase / (Decrease) | Nine Months Ended September 30, 2025 | 2024 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $3.1 | $3.0 | $0.1 | $9.4 | $5.7 | $3.7 |
| Cost of revenue | 2.2 | 2.0 | 0.2 | 6.6 | 3.7 | 2.9 |
| Selling, general and administrative | 3.6 | 4.2 | (0.6) | 11.1 | 12.2 | (1.1) |
| Depreciation and amortization | 0.1 | 0.1 | — | 0.3 | 0.3 | — |
| Loss from operations | $(2.8) | $(3.3) | $0.5 | $(8.6) | $(10.5) | $1.9 |

*Revenue*: Revenue for the three months ended September 30, 2025, increased $0.1 million to $3.1 million from $3.0 million for the three months ended September 30, 2024. The increase was attributable to R2 Technologies, primarily driven by increases in Glacial Spa unit sales and Glacial fx unit sales outside North America, as well as an increase in consumable sales in North America. The increase was mostly offset by a decrease in Glacial fx unit sales in North America and a decrease in consumable sales outside North America.

Revenue for the nine months ended September 30, 2025, increased $3.7 million to $9.4 million from $5.7 million for the nine months ended September 30, 2024. The increase in revenue was attributable to R2 Technologies, primarily driven by an increase in Glacial Spa and Glacial fx unit sales outside North America, as well as an increases in consumable sales and Glacial fx and Glacial Rx unit sales in North America.

*Cost of revenue*: Cost of revenue for the three months ended September 30, 2025, increased $0.2 million to $2.2 million from $2.0 million for the three months ended September 30, 2024. Cost of revenue for the nine months ended September 30, 2025, increased $2.9 million to $6.6 million from $3.7 million for the nine months ended September 30, 2024. The increases in cost of revenue were attributable to R2 Technologies, primarily driven by the increase in revenue from the additional unit system and consumables sales noted above and, to a lesser extent, the related increases in warranty expenses, royalty expenses, and freight costs. The increase in cost of revenue was partially offset by changes in product mix sold as the Glacial fx and Glacial Spa systems have a lower production cost per system compared to the Glacial Rx.

*Selling, general and administrative*: Selling, general and administrative expense for the three months ended September 30, 2025 decreased $0.6 million to $3.6 million from $4.2 million for the three months ended September 30, 2024. Selling, general and administrative expense for the nine months ended September 30, 2025, decreased $1.1 million to $11.1 million from $12.2 million for the nine months ended September 30, 2024. The decreases were primarily driven by a reduction in compensation-related expenses at Pansend.

### Spectrum Segment

|  | Three Months Ended September 30, 2025 | 2024 | Increase / (Decrease) | Nine Months Ended September 30, 2025 | 2024 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $5.6 | $6.4 | $(0.8) | $17.5 | $18.9 | $(1.4) |
| Cost of revenue | 2.9 | 2.9 | — | 8.7 | 8.7 | — |
| Selling, general and administrative | 2.0 | 1.9 | 0.1 | 5.8 | 5.6 | 0.2 |
| Depreciation and amortization | 1.2 | 1.3 | (0.1) | 3.6 | 3.9 | (0.3) |
| Other operating (income) loss | (0.4) | 0.4 | (0.8) | (0.4) | 0.5 | (0.9) |
| (Loss) income from operations | $(0.1) | $(0.1) | $— | $(0.2) | $0.2 | $(0.4) |

*Revenue:* Revenue for the three months ended September 30, 2025, decreased $0.8 million to $5.6 million from $6.4 million for the three months ended September 30, 2024. The decrease was primarily driven by the termination of certain customers in the current period and a downturn in the direct response advertising market.

Revenue for the nine months ended September 30, 2025, decreased $1.4 million to $17.5 million from $18.9 million for the nine months ended September 30, 2024. The decrease was primarily driven by the termination of certain customers in the current period and a downturn in the direct response advertising market, which was partially offset by the launch of new networks subsequent to the comparable period.

*Selling, general and administrative*: Selling, general and administrative for the three months ended September 30, 2025 increased slightly by $0.1 million to $2.0 million from 1.9 million for the three months ended September 30, 2024. Selling, general and administrative for the nine months ended September 30, 2025 increased slightly by $0.2 million to $5.8 million from $5.6 million for the nine months ended September 30, 2024.

*Depreciation and amortization*: Depreciation and amortization for the three months ended September 30, 2025, decreased slightly by $0.1 million to $1.2 million from $1.3 million for the three months ended September 30, 2024. Depreciation and amortization for the nine months ended September 30, 2025, decreased by $0.3 million to $3.6 million from $3.9 million for the nine months ended September 30, 2024.

*Other operating (income) loss*: Other operating (income) loss for the three months ended September 30, 2025, increased $0.8 million to income of $0.4 million from a loss of $0.4 million for three months ended September 30, 2024. Other operating (income) loss for the nine months ended September 30, 2025, increased $0.9 million to income of $0.4 million from a loss of 0.5 million for nine months ended September 30, 2024. The increases in income were primarily driven by a favorable legal settlement in the current period and unrepeated lease termination settlement costs incurred in the comparable period.

### Non-Operating Corporate

|  | Three Months Ended September 30, 2025 | 2024 | Increase / (Decrease) | Nine Months Ended September 30, 2025 | 2024 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative | $7.0 | $3.0 | $4.0 | $12.5 | $9.0 | $3.5 |
| Depreciation and amortization | — | — | — | — | 0.1 | (0.1) |
| Other operating loss | — | — | — | — | 0.2 | (0.2) |
| Loss from operations | $(7.0) | $(3.0) | $(4.0) | $(12.5) | $(9.3) | $(3.2) |

*Selling, general and administrative*: Selling, general and administrative expenses for the three months ended September 30, 2025, increased $4.0 million to $7.0 million from $3.0 million for the three months ended September 30, 2024. The increase was primarily driven by $4.3 million in debt refinancing costs expensed in the current period and an increase in share-based compensation expense related to the vesting and issuance of equity awards to our Interim-CEO, which awards had not yet been vested or granted in the comparable period, which were partially offset by a decrease in other legal fees due to legal matters settled subsequent to the comparable period, as well as slight decreases in other professional expenses, insurance expense and other employee-related expenses.

Selling, general and administrative expenses for the nine months ended September 30, 2025 increased 3.5 million to $12.5 million from $9.0 million for the nine months ended September 30, 2024. The increase was primarily driven by $4.3 million in debt refinancing costs expensed in the current period and an increase in share-based compensation expense related to the vesting and issuance of equity awards to our Interim-CEO, which awards had not yet been vested or granted in the comparable period, which were partially offset by a decrease in other legal fees due to legal matters settled subsequent to the comparable period, as well as decreases in other employee-related expenses, accounting and insurance expense.

*Depreciation and amortization:* Depreciation and amortization for the nine months ended September 30, 2025, decreased to zero from $0.1 million for the nine months ended September 30, 2024. The decrease was driven by assets that were fully depreciated subsequent to the comparable period.

*Other operating loss:* Other operating loss for the nine months ended September 30, 2025, decreased to zero from $0.2 million for the nine months ended September 30, 2024. Other operating loss for the nine months ended September 30, 2024 related to lease termination costs for two leases exited by the Company.

### Loss from Equity Investees

|  | Three Months Ended September 30, 2025 | 2024 | (Increase) / Decrease | Nine Months Ended September 30, 2025 | 2024 | (Increase) / Decrease |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Life Sciences | $— | $— | $— | $(5.9) | $(2.3) | $(3.6) |
| Loss from equity investees | $— | $— | $— | $(5.9) | $(2.3) | $(3.6) |

*Life Sciences:* Loss from equity investees within our Life Sciences segment for the nine months ended September 30, 2025, increased $3.6 million to $5.9 million from $2.3 million for the nine months ended September 30, 2024. The increase in loss was due to an increase in losses recognized from MediBeacon. During the nine months ended September 30, 2025, as a result of the first quarter equity transactions that occurred upon FDA approval of MediBeacon's TGFR, Pansend's basis in MediBeacon increased by $5.9 million, consisting of a $4.4 million step-up gain and $1.5 million from the conversion of accrued interest on Pansend's convertible notes with MediBeacon, resulting in Pansend recognizing $5.9 million of equity method losses that were previously unrecognized. During the nine months ended September 30, 2024, Pansend's basis in MediBeacon had increased by $2.3 million due to the issuance of additional convertible note investments in the comparable period, resulting in Pansend recognizing $2.3 million of equity method losses that were previously unrecognized. As of both September 30, 2025 and 2024, Pansend's net carrying amount of its investment in MediBeacon was zero, and Pansend had unrecognized losses from this investment.

Refer to Note 6. Investments to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on our equity investments.

### Non-GAAP Financial Measures and Other Information

#### Adjusted EBITDA

Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-U.S. GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) attributable to INNOVATE Corp., excluding: discontinued operations, if applicable; depreciation and amortization; other operating (income) loss, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, (gains) losses on lease modifications, and asset impairment expense; interest expense; other (income) expense, net; income tax expense (benefit); non-controlling interest; share-based compensation expense; realignment and exit costs; debt refinancing costs; and acquisition and disposition costs.

Adjusted EBITDA by segment is summarized as follows:

| (in millions): | Three Months Ended September 30, 2025 | 2024 | Increase / (Decrease) | Nine Months Ended September 30, 2025 | 2024 | Increase / (Decrease) |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Infrastructure | $23.5 | $20.9 | $2.6 | $59.5 | $71.7 | $(12.2) |
| Life Sciences | (2.6) | (3.0) | 0.4 | (13.9) | (12.0) | (1.9) |
| Spectrum | 1.0 | 1.7 | (0.7) | 3.4 | 4.8 | (1.4) |
| Non-Operating Corporate | (2.1) | (2.8) | 0.7 | (6.3) | (8.2) | 1.9 |
| Other and Eliminations | — | — | — | — | — | — |
| Adjusted EBITDA | $19.8 | $16.8 | $3.0 | $42.7 | $56.3 | $(13.6) |

51

The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp. to Adjusted EBITDA for the three months ended September 30, 2025 and 2024:

*(in millions)*

|  | Three Months Ended September 30, 2025 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $8.8 | $(4.6) | $(5.9) | $(7.2) | $— | $(8.9) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 3.0 | 0.1 | 1.2 | — | — | 4.3 |
| Depreciation and amortization (included in cost of revenue) | 3.2 | — | — | — | — | 3.2 |
| Other operating loss (income) | 0.1 | — | (0.4) | — | — | (0.3) |
| Interest expense | 2.4 | 3.1 | 3.8 | 14.1 | — | 23.4 |
| Other (income) expense, net | (0.5) | (0.1) | 2.4 | (2.4) | — | (0.6) |
| Income tax expense (benefit) | 4.4 | — | — | (11.5) | — | (7.1) |
| Non-controlling interest | 0.9 | (1.2) | (0.4) | — | — | (0.7) |
| Share-based compensation expense | — | 0.1 | — | 0.6 | — | 0.7 |
| Realignment and exit costs | 1.2 | — | 0.1 | — | — | 1.3 |
| Debt refinancing costs | — | — | 0.2 | 4.3 | — | 4.5 |
| Adjusted EBITDA | $23.5 | $(2.6) | $1.0 | $(2.1) | $— | $19.8 |

*(in millions)*

|  | Three Months Ended September 30, 2024 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $6.2 | $(6.0) | $(5.6) | $(9.6) | $— | $(15.0) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 3.0 | 0.1 | 1.3 | — | — | 4.4 |
| Depreciation and amortization (included in cost of revenue) | 3.7 | — | — | — | — | 3.7 |
| Other operating loss | 0.1 | — | 0.4 | — | — | 0.5 |
| Interest expense | 3.0 | 4.5 | 3.8 | 9.9 | — | 21.2 |
| Other expense (income), net | 0.3 | (0.5) | 2.2 | (4.2) | — | (2.2) |
| Income tax expense | 2.3 | — | — | 0.8 | — | 3.1 |
| Non-controlling interest | 0.6 | (1.3) | (0.5) | — | — | (1.2) |
| Share-based compensation expense | — | 0.1 | — | 0.2 | — | 0.3 |
| Realignment and exit costs | 1.4 | — | — | — | — | 1.4 |
| Acquisition and disposition costs | 0.3 | 0.1 | 0.1 | 0.1 | — | 0.6 |
| Adjusted EBITDA | $20.9 | $(3.0) | $1.7 | $(2.8) | $— | $16.8 |

*Infrastructure:* Net income from our Infrastructure segment for the three months ended September 30, 2025, increased $2.6 million to $8.8 million from $6.2 million for the three months ended September 30, 2024. Adjusted EBITDA from our Infrastructure segment for the three months ended September 30, 2025, increased $2.6 million to $23.5 million from $20.9 million for the three months ended September 30, 2024. The increase in Adjusted EBITDA was primarily driven by the increase in revenue and gross profit at DBMG's commercial structural steel fabrication and erection business, which had increased activity subsequent to the comparable period on certain large commercial construction projects, an improvement in gross profit at Banker Steel, and a decrease in recurring SG&A expenses primarily due to a decrease in compensation-related expenses and consulting fees. These increases were partially offset by the decrease in revenue and gross profit at the industrial maintenance and repair business due to increased activity in the comparable period on certain large commercial construction and industrial maintenance projects that have since been completed.

*Life Sciences:* Net loss from our Life Sciences segment for the three months ended September 30, 2025, decreased $1.4 million to $4.6 million from $6.0 million for the three months ended September 30, 2024. Adjusted EBITDA loss from our Life Sciences segment for the three months ended September 30, 2025, decreased $0.4 million to $2.6 million from $3.0 million for the three months ended September 30, 2024. The decrease in Adjusted EBITDA loss was primarily driven by a reduction in compensation-related expenses at Pansend.

*Spectrum:* Net loss from our Spectrum segment for the three months ended September 30, 2025, increased $0.3 million to $5.9 million from $5.6 million for the three months ended September 30, 2024. Adjusted EBITDA from our Spectrum segment for the three months ended September 30, 2025, decreased $0.7 million to $1.0 million from $1.7 million for the three months ended September 30, 2024. The decrease in Adjusted EBITDA was primarily driven by the termination of certain customers in the current period and a downturn in the direct response advertising market.

*Non-Operating Corporate:* Net loss from our Non-Operating Corporate segment for the three months ended September 30, 2025, decreased $2.4 million to $7.2 million from $9.6 million for the three months ended September 30, 2024. Adjusted EBITDA loss from our Non-Operating Corporate segment for the three months ended September 30, 2025, decreased $0.7 million to $2.1 million from $2.8 million for the three months ended September 30, 2024. The decrease in Adjusted EBITDA loss was primarily driven by a decrease in non-refinancing related legal fees due to legal matters settled subsequent to the comparable period, as well as slight decreases in other professional expenses, insurance expense, and employee-related expenses.

The tables below provide reconciliations of net income (loss) attributable to INNOVATE Corp. to Adjusted EBITDA for the nine months ended September 30, 2025 and 2024:

*(in millions)*

|  | Nine Months Ended September 30, 2025 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $18.9 | $(18.7) | $(17.4) | $(36.0) | $— | $(53.2) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 9.2 | 0.3 | 3.6 | — | — | 13.1 |
| Depreciation and amortization (included in cost of revenue) | 9.7 | — | — | — | — | 9.7 |
| Other operating loss (income) | 1.2 | — | (0.4) | — | — | 0.8 |
| Interest expense | 6.9 | 12.8 | 11.4 | 33.9 | — | 65.0 |
| Other (income) expense, net | (0.8) | (4.6) | 6.9 | (5.8) | — | (4.3) |
| Income tax expense (benefit) | 8.8 | — | — | (4.6) | — | 4.2 |
| Non-controlling interest | 1.9 | (4.0) | (1.1) | — | — | (3.2) |
| Share-based compensation expense | — | 0.3 | — | 1.9 | — | 2.2 |
| Realignment and exit costs | 3.6 | — | 0.2 | — | — | 3.8 |
| Debt refinancing costs | 0.1 | — | 0.2 | 4.3 | — | 4.6 |
| Adjusted EBITDA | $59.5 | $(13.9) | $3.4 | $(6.3) | $— | $42.7 |

*(in millions)*

|  | Nine Months Ended September 30, 2024 Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income (loss) attributable to INNOVATE Corp. | $31.6 | $(14.3) | $(15.4) | $(20.0) | $0.1 | $(18.0) |
| Adjustments to reconcile net income (loss) to Adjusted EBITDA: |  |  |  |  |  |  |
| Depreciation and amortization | 8.9 | 0.3 | 3.9 | 0.1 | — | 13.2 |
| Depreciation and amortization (included in cost of revenue) | 11.5 | 0.1 | — | — | — | 11.6 |
| Other operating (income) loss | (8.8) | — | 0.5 | 0.2 | — | (8.1) |
| Interest expense | 7.7 | 6.4 | 10.6 | 30.2 | — | 54.9 |
| Other (income) expense, net | (0.8) | 1.2 | 6.3 | (7.8) | (0.1) | (1.2) |
| Income tax expense (benefit) | 15.7 | — | — | (11.8) | — | 3.9 |
| Non-controlling interest | 3.0 | (6.1) | (1.3) | — | — | (4.4) |
| Share-based compensation expense | — | 0.3 | — | 0.8 | — | 1.1 |
| Realignment and exit costs | 2.6 | — | — | — | — | 2.6 |
| Acquisition and disposition costs | 0.3 | 0.1 | 0.2 | 0.1 | — | 0.7 |
| Adjusted EBITDA | $71.7 | $(12.0) | $4.8 | $(8.2) | $— | $56.3 |

53

*Infrastructure:* Net income from our Infrastructure segment for the nine months ended September 30, 2025, decreased $12.7 million to $18.9 million from $31.6 million for the nine months ended September 30, 2024. Adjusted EBITDA from our Infrastructure segment for the nine months ended September 30, 2025, decreased $12.2 million to $59.5 million from $71.7 million for the nine months ended September 30, 2024. The decrease in Adjusted EBITDA was primarily driven by a decrease in gross profit, despite the increase in revenue, at DBMG's commercial structural steel fabrication and erection business, and the decrease in revenue and gross profit at Banker Steel due to timing of certain large commercial construction projects that have since been completed or are nearing completion in the current period. These decreases were partially offset by an improvement in gross profit at the industrial maintenance and repair business, and a decrease in recurring SG&A expenses, primarily driven by a decrease in compensation-related expenses primarily due to timing, and to a lesser extent, decreases in consulting fees and travel expenses.

*Life Sciences:* Net loss from our Life Sciences segment for the nine months ended September 30, 2025, increased $4.4 million to $18.7 million from $14.3 million for the nine months ended September 30, 2024. Adjusted EBITDA loss from our Life Sciences segment for the nine months ended September 30, 2025, increased $1.9 million to $13.9 million from $12.0 million for the nine months ended September 30, 2024. The increase in Adjusted EBITDA loss was primarily due to an increase in equity method losses recognized from MediBeacon, as discussed in the *Loss from Equity Investees* section above. The increase in Adjusted EBITDA loss was partially offset by a decrease in SG&A expenses primarily driven by a reduction in compensation-related expenses at Pansend and an increase in gross profit at R2 Technologies, driven by increased revenue (as discussed in the *Revenue* section above).

*Spectrum:* Net loss from our Spectrum segment for the nine months ended September 30, 2025, increased $2.0 million to $17.4 million from $15.4 million for the nine months ended September 30, 2024. Adjusted EBITDA from our Spectrum segment for the nine months ended September 30, 2025, decreased $1.4 million to $3.4 million from $4.8 million for the nine months ended September 30, 2024. The decrease in Adjusted EBITDA was primarily driven by the termination of certain customers in the current period and a downturn in the direct response advertising market, which was partially offset by the launch of new networks subsequent to the comparable period.

*Non-Operating Corporate:* Net loss from our Non-Operating Corporate segment for the nine months ended September 30, 2025, increased $16.0 million to $36.0 million from $20.0 million for the nine months ended September 30, 2024. Adjusted EBITDA loss from our Non-Operating Corporate segment for the nine months ended September 30, 2025, decreased $1.9 million to $6.3 million from $8.2 million for the nine months ended September 30, 2024. The decrease in Adjusted EBITDA loss was primarily driven by a decrease in non-refinancing related legal fees due to legal matters settled subsequent to the comparable period, as well as decreases in employee-related expenses, accounting and insurance expense.

### Backlog

Backlog is our estimate of the U.S. dollar amount of future revenues we expect to realize as a result of performing work on projects in backlog. Projects in backlog consist of awarded contracts, letters of intent, notices to proceed, change orders, and purchase orders obtained. Backlog increases as contract commitments are obtained, decreases as revenues are recognized and increases or decreases to reflect modifications in the work to be performed under the contracts. Backlog is converted to sales in future periods as work is performed or projects are completed. Backlog can be significantly affected by the receipt or loss of individual contracts.

#### Infrastructure Segment

As of September 30, 2025, DBMG's backlog was $1,548.4 million, consisting of $1,483.7 million under contracts or purchase orders and $64.7 million under letters of intent or notices to proceed. Approximately $1,022.6 million, representing 66.0% of DBMG’s backlog as of September 30, 2025, was attributable to five contracts, letters of intent, notices to proceed or purchase orders. If one or more of these projects terminate or reduce their scope, DBMG’s backlog could decrease substantially. DBMG has included an additional $10.7 million in its backlog that is not included in the remaining unsatisfied performance obligations disclosed in Note 3. Revenue and Contracts in Process. This additional backlog includes commitments under master service agreements that are estimated amounts of work to be performed based on customer communications, historic performance and knowledge of our customers' intentions.

### Liquidity and Capital Resources

### 2025 Debt Refinancing

In August 2025, the Company closed on a series of indebtedness refinancing transactions that extended certain of the Company’s debt maturities. The refinancing transactions included: (i) the closings of an exchange offer and consent solicitation with respect to the Company’s senior secured notes; (ii) privately negotiated exchanges of certain of the Company’s convertible senior notes; (iii) amendment and extension of the Company’s 2020 Revolving Credit Agreement; (iv) amendment and extension of the Company’s CGIC note, as well as the exchange of a portion of the Company’s preferred stock held by CGIC and accrued preferred stock dividends in exchange for increasing the principal amount of that note; (v) amendment and extension of the Spectrum debt; and (vi) amendment and extension of the R2 Technologies debt. In addition, on May 20, 2025, DBMG entered into an Amended and Restated Credit Agreement. Total third-party fees expensed related to the refinancing transactions were $4.5 million and $4.6 million for the three and nine months ended September 30, 2025, respectively, and total third party fees capitalized were $0.4 million and $2.1 million for the three and nine months ended September 30, 2025, respectively. Refer to “*Indebtedness”* below and to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Indebtedness

### Non-Operating Corporate

#### 10.50% Senior Secured Notes due 2027

In August 2025, we closed on an exchange offer and consent solicitation to eligible holders of our 8.50% senior secured notes due 2026 ("8.50% 2026 Senior Secured Notes") to exchange such notes for newly issued 10.50% senior secured notes due 2027 (the “10.50% 2027 Senior Secured Notes”). The Company, the guarantors party thereto from time to time and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “10.50% 2027 Senior Secured Notes Trustee”) and collateral trustee, entered into an indenture (the “10.50% 2027 Senior Secured Notes Indenture”) governing the 10.50% 2027 Senior Secured Notes and we issued $360.4 million aggregate principal amount of 10.50% senior secured notes due 2027 (the "10.50% 2027 Senior Secured Notes"), at 100% of par, as consideration for the exchange of $328.1 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes. The new principal amount includes fees payable to the lenders and $52.50 principal amount of 10.50% 2027 Senior Secured Notes per $1,000 principal amount of 8.50% 2026 Senior Secured Notes exchanged, paid to exchanging holders in lieu of the interest payment in respect of the 8.50% 2026 Senior Secured Notes that was due on August 1, 2025).

The 10.50% 2027 Senior Secured Notes mature on February 1, 2027 and accrue interest at a rate of 10.50% per year, payable semi-annually on February 1st and August 1st of each year, commencing on February 1, 2026. For the first interest period only, interest will be paid in kind. All subsequent interest payments are payable in cash.

As of September 30, 2025, the total carrying amount related to the note was $342.6 million, inclusive of $360.4 million aggregate principal outstanding, partially offset by a $16.6 million total unamortized discount and $1.2 million of total unamortized deferred financing fees. The effective interest rate on the 10.50% 2027 Senior Secured Notes was 14.4% as of September 30, 2025. Aggregate interest expense for the new 10.50% 2027 Senior Secured Notes, including the contractual interest coupon and amortization of fees was $8.2 million for both the three and nine months ended September 30, 2025.

Our obligations under the 10.50% 2027 Senior Secured Notes Indenture are irrevocably and unconditionally guaranteed, jointly and severally, by the same guarantors that guarantee the 8.50% 2026 Senior Secured Notes (the “Subsidiary Guarantors”). The 10.50% 2027 Senior Secured Notes and the related guarantees are senior secured obligations of the Company and the Subsidiary Guarantors.

*Asset Sale Offer.* If we complete certain assets sales, we may be required in certain circumstances to make an offer to purchase the 10.50% 2027 Senior Secured Notes with the net cash proceeds from such an asset sale at a price in cash equal to 101% of the principal amount thereof, together with accrued and unpaid interest, if any, to the date of purchase.

*Certain Covenants.* The 10.50% 2027 Senior Secured Notes Indenture contains covenants limiting, among other things, our ability, and, in certain cases, our subsidiaries' ability, to incur additional indebtedness; create liens; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in certain transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. Additionally, the 10.50% 2027 Senior Secured Notes Indenture requires us to meet certain milestones with respect to strategic alternatives for our operating subsidiaries, including asset sales generating at least $150 million in net proceeds, such that by September 1, 2025 we have a bona fide bid or term sheet related to a potential sale, a fully executed purchase or equity agreement by November 1, 2025, and an executed transaction with applied proceeds to the 10.50% 2027 Senior Secured Notes Indenture no later than February 1, 2026. In the event a milestone is not reached, we will be required to commence a sales process for DBM Global. These covenants are subject to a number of important exceptions and qualifications. As of September 30, 2025, the September 1, 2025 milestone was not reached, and we have thus initiated a sales process for DBMG and we are in compliance with the milestone covenants requirements.

Any failure to comply with the restrictions or covenants in the indentures governing INNOVATE’s 2027 Senior Secured Notes and 2027 Convertible Notes, or any other agreement governing our existing indebtedness or indebtedness we may incur in the future, may result in an event of default under those agreements. Such default may allow the creditors to accelerate the related debt, which acceleration may trigger cross-acceleration or cross-default provisions in other debt.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

#### 8.50% Senior Secured Notes due 2026

The original $330.0 million aggregate principal amount of 8.50% senior secured notes due February 1, 2026 (the "8.50% 2026 Senior Secured Notes") were issued in 2021 at 100% of par. In August 2025, we exchanged $328.1 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes for new 10.50% 2027 Senior Secured Notes, as discussed above. As of September 30, 2025, we had $1.9 million aggregate principal amount of the 8.50% 2026 Senior Secured Notes remaining with an effective interest rate of 9.3%.

Interest is payable semi-annually in arrears on February 1st and August 1st of each year. Aggregate interest expense, including the contractual interest coupon and amortization of the deferred financing fees was $2.6 million and $17.9 million for the three and nine months ended September 30, 2025, respectively.

On August 4, 2025, the Company and U.S. Bank Trust Company, National Association, as trustee (the “8.50% 2026 Senior Secured Notes Trustee”), entered into a first supplemental indenture (the “8.50% 2026 Senior Secured Notes Supplemental Indenture”) to the indenture dated as of February 1, 2021, by and among the Company, the guarantors party thereto from time to time and the 8.50% 2026 Senior Secured Notes Trustee, governing the 8.50% 2026 Senior Secured Notes (the “8.50% 2026 Senior Secured Notes Indenture”). The 8.50% 2026 Senior Secured Notes Supplemental Indenture amended the 8.50% 2026 Senior Secured Notes Indenture and the 8.50% 2026 Senior Secured Notes to effectuate certain proposed amendments with respect to the 8.50% 2026 Senior Secured Notes pursuant to the solicitation of consents, which amendments included eliminating substantially all of the restrictive covenants, eliminating certain events of default, modifying covenants regarding mergers and consolidations and modifying or eliminating certain other provisions contained in the 8.50% 2026 Senior Secured Notes Indenture and the 8.50% 2026 Senior Secured Notes. In addition, the liens securing the 8.50% 2026 Senior Secured Notes were subordinated to the liens securing certain indebtedness, including the new 10.50% 2027 Senior Secured Notes, the new 2027 Convertible Notes as defined below and the 2020 Revolving Credit Agreement as defined below pursuant to the 8.50% 2026 Senior Secured Notes Supplemental Indenture.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

#### 2027 Convertible Notes

On August 4, 2025, we settled the exchanges (collectively, the “Convertible Notes Exchanges”) under our privately negotiated exchange agreements (collectively, the “Exchange Agreements”) with certain holders of its 7.5% Convertible Senior Notes due 2026 ("the 2026 Convertible Notes"). Pursuant to the Exchange Agreements, we exchanged $48.7 million of the then outstanding aggregate principal amount of the 2026 Convertible Notes for $53.5 million aggregate principal amount of newly issued 9.5% Convertible Senior Secured Notes due 2027 (the “2027 Convertible Notes”), which is the total outstanding as of September 30, 2025. The 2027 Convertible Notes were issued at 100% of par and mature on March 1, 2027 unless earlier converted, redeemed or purchased. The new principal amount includes fees payable to the lenders and $47.50 principal amount of 2027 Convertible Notes per $1,000 principal amount of 2026 Convertible Notes exchanged, paid to exchanging holders in lieu of the interest payment in respect of the 2026 Convertible Notes that was due on August 1, 2025.

As of September 30, 2025, the total carrying amount related to the note was $52.3 million, inclusive of $53.5 million aggregate principal outstanding, partially offset by a remaining unamortized net discount of $1.0 million and unamortized deferred financing fees of $0.2 million.

The 2027 Convertible Notes accrue interest at a rate of 9.5% per year. The effective interest rate on the 2027 Convertible Notes is 11.1%. Interest on the 2027 Convertible Notes is paid semi-annually on February 1st and August 1st of each year, commencing on February 1, 2026. For the first interest period only, interest will be paid in kind. All subsequent interest payments are payable in cash. Aggregate interest expense, including the contractual interest coupon and amortization of the deferred financing fees and net discount was $1.0 million for both the three and nine months ended September 30, 2025.

The Company, the guarantors party thereto from time to time and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “2027 Convertible Notes Trustee”) and collateral trustee, entered into an indenture (the “2027 Convertible Notes Indenture”), dated as of August 4, 2025, governing the 2027 Convertible Notes.

*Certain Covenants.* The 2027 Convertible Notes Indenture contains covenants limiting, among other things, our ability, and, in certain cases, our subsidiaries' ability, to incur additional indebtedness; create liens; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in certain transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. These covenants are subject to a number of important exceptions and qualifications.

Any failure to comply with the restrictions or covenants in the indentures governing INNOVATE’s 2027 Senior Secured Notes and 2027 Convertible Notes, or any other agreement governing our existing indebtedness or indebtedness we may incur in the future, may result in an event of default under those agreements. Such default may allow the creditors to accelerate the related debt, which acceleration may trigger cross-acceleration or cross-default provisions in other debt.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

#### 2026 Convertible Notes

The original $51.8 million aggregate principal amount of 7.50% convertible notes (the "2026 Convertible Notes") were issued under an indenture dated February 1, 2021, between the Company and U.S. Bank, as trustee. During July 2024, INNOVATE repurchased $2.9 million principal amount of its 2026 Convertible Notes at a market discount for $1.1 million, which was inclusive of accrued interest of $0.1 million. As discussed above, on August 4, 2025, pursuant to the Exchange Agreements, we exchanged $48.7 million aggregate principal amount of the 2026 Convertible Notes for new 2027 Convertible Notes. Subsequent to the exchanges and, as of September 30, 2025, we had $0.2 million aggregate principal remaining of the 2026 Convertible Notes.

The 2026 Convertible Notes mature on August 1, 2026, unless earlier converted, redeemed or purchased. The 2026 Convertible Notes accrue interest at a rate of 7.5% per year, which interest is paid semi-annually in arrears on February 1st and August 1st of each year. As of September 30, 2025, the effective interest rate on the 2026 Convertible Notes was 3.0%. Aggregate interest expense recognized relating to both the contractual interest coupon and amortization of discount net of premium and deferred financing costs was $0.1 million and $0.9 million for the three and nine months ended September 30, 2025 respectively.

On August 4, 2025, the Company and U.S. Bank Trust Company, National Association, as trustee (the “2026 Convertible Notes Trustee”) entered into a first supplemental indenture (the “2026 Convertible Notes Supplemental Indenture”) to the indenture, dated as of February 1, 2021, by and among the Company, the guarantors party thereto from time to time and the 2026 Convertible Notes Trustee, governing the 2026 Convertible Notes (the “2026 Convertible Notes Indenture”). The 2026 Convertible Notes Supplemental Indenture amended the 2026 Convertible Notes Indenture and the 2026 Convertible Notes to effectuate certain proposed amendments with respect to the 2026 Convertible Notes pursuant to the solicitation of consents, which amendments included eliminating substantially all of the restrictive covenants, eliminating certain events of default, modifying covenants regarding mergers and consolidations and modifying or eliminating certain other provisions, contained in the 2026 Convertible Notes Indenture and the 2026 Convertible Notes.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Our debt contains customary events of default which could, subject to certain conditions, cause the 2026 Senior Secured Notes and the 2026 Convertible Notes to become immediately due and payable.

#### Revolving Line of Credit

We have a revolving credit agreement with MSD PCOF Partners IX, LLC ("MSD") which has a maximum commitment of $20.0 million ("Revolving Line of Credit"), of which $20.0 million had been drawn as of September 30, 2025. Interest on loans under the Revolving Line of Credit accrues at SOFR plus 5.75% and is payable quarterly. On August 4, 2025, the Company and MSD entered into an Eighth Amendment to Credit Agreement, which among other things, extended the maturity of the 2020 Revolving Credit Agreement to September 15, 2026 and added a new $0.4 million extension fee that is payable on the earlier of the maturity date or date of prepayment of the debt.

The Revolving Line of Credit has an interest rate margin applicable to loans borrowed under the Revolving Line of Credit of 5.75%, and the benchmark rates for the interest are SOFR-based rates. As of September 30, 2025, the effective interest rate on the Revolving Line of Credit, as amended, was 10.0%. Interest is paid quarterly in arrears. The Revolving Line of Credit also includes a commitment fee at a per annum rate of 1.0% calculated based off the actual daily amount of unused availability under the Revolving Line of Credit with MSD, and also includes a requirement for prepayment using the net cash proceeds received from certain asset sales. The affirmative and negative covenants governing the Revolving Line of Credit are substantially consistent with the affirmative and negative covenants contained in the indenture that governs the Company's senior secured notes.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

#### CGIC Promissory Note

On August 4, 2025, we entered into a Subordinated Secured Promissory Note with CGIC to, among other things, extend the maturity of its existing subordinated unsecured promissory note with CGIC (the “CGIC Note”) from February 28, 2026 to April 30, 2027, and secure the amended CGIC Note by a third priority lien on the same collateral securing the 10.50% 2027 Senior Secured Notes and the 2027 Convertible Notes. The amended CGIC Note has an interest rate of 16.0%, and an effective interest rate of 14.6% as of September 30, 2025. Interest on the amended CGIC Note will be paid on a monthly basis and in kind through August 31, 2026. All interest payments thereafter will be payable in cash, in arrears.

As part of the agreement with CGIC, the accrued value of 8,063 shares of Series A-4 Preferred Stock of the Company held by CGIC, and unpaid accrued cash dividends for the A-3 and A-4 Preferred Stock were exchanged for an additional principal amount of the CGIC Note, on a dollar-for-dollar basis (the “Preferred Stock Exchange”). The additional principal amount incurred under the Preferred Stock Exchange was $9.6 million (reflective of the $9.1 million accrued value of the Series A-4 Preferred Stock and $0.5 million in accrued dividends on the Series A-3 and A-4 Preferred Stock). In addition, an extension fee and accrued interest of $2.4 million on the CGIC Note through July 31, 2025, were capitalized to the new principal amount of the CGIC Note, for a total new aggregate outstanding principal amount of $43.0 million. As of September 30, 2025 the total carrying amount related to the note was $45.1 million, inclusive of $44.1 million of principal (including capitalized interest), and a net unamortized premium of $1.0 million. For the three and nine months ended September 30, 2025, interest expense recognized relating to the CGIC Note, including the contractual interest coupon and amortization of the deferred financing fees and discounts, was $1.5 million and $4.2 million, respectively.

*Mandatory Prepayment*s. After the indefeasible repayment and satisfaction in full in cash of all obligations under the 10.50% 2027 Senior Secured Notes, the 10.50% 2027 Senior Secured Notes Indenture, the 2027 Convertible Notes, the 2027 Convertible Notes Indenture and all other Senior Debt (or, in each case, under any refinancing indebtedness in respect thereof), the Company must prepay the CGIC Note (together with all accrued and unpaid interest and all other amounts payable under the CGIC Note) upon the occurrence of an Asset Sale (as defined in the agreement), in an amount equal to the Net Cash Proceeds (as defined in the agreement) from such Asset Sale, with such prepayment due no later than two (2) Business Days after the receipt of such Net Cash Proceeds by the Company (or its subsidiary, if applicable) from such Asset Sale.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

### Infrastructure

As of September 30, 2025, our Infrastructure segment has an aggregate amount of principal outstanding debt, including obligations under finance leases, of $104.1 million.

On May 20, 2025, DBMG entered into an Amended and Restated Credit agreement (the "DBMG Credit Agreement"), with the lenders which are party thereto from time to time (each a “Lender” and collectively the “Lenders”) and UMB BANK, N.A. ("UMB"). The DBMG Credit Agreement provides DBMG with senior secured debt financing in an amount up to $220.0 million in the aggregate, consisting of (i) a senior secured revolving credit facility (the “DBMG Revolving Facility”) in an aggregate amount of $135.0 million and (ii) a senior secured term loan facility in the amount of $85.0 million. The DBMG Credit Agreement also contains an accordion feature to increase the allowable size of the DBMG Revolving Facility by an additional $50.0 million. The DBMG Revolving Facility and the term loan facility will mature on May 20, 2030. DBMG entered into the DBMG Credit Agreement to fully repay DBMG’s existing debt obligations and provide additional working capital capacity.

The term loan and borrowings under the new DBMG Credit Agreement bear interest at a rate per annum equal to a SOFR Rate plus a variable spread based on a Senior Funded Indebtedness to EBITDA Ratio as defined in the agreement with an interest rate floor of 4.25% per annum. As of September 30, 2025, DBMG had a total outstanding balance of $20.0 million under its Revolving Facility and the effective interest rate on DBMG's revolving loans was 7.28%. Interest on the new revolving facility is paid monthly and the new revolving facility has an unused commitment fee of 0.50% per annum times the average daily unused availability under the line.

As of September 30, 2025, the total outstanding balance of DBMG's term loans was $83.9 million, and the effective interest rate was 7.87%. Principal payments and interest on DBMG's term loans are paid monthly. DBMG had availability for revolving loans of $114.9 million as of September 30, 2025.

The DBMG Credit Agreement contains usual and customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio; and a Senior Funded Indebtedness to EBITDA Ratio, both as defined in the DBMG Credit Agreement.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Life Sciences

As of September 30, 2025, our Life Sciences segment has aggregate principal outstanding debt of $46.5 million with Lancer, a related party.

On August 4, 2025, Lancer and R2 Technologies entered into an Amended and Restated Senior Secured Promissory Note (the "Lancer Note"), which was previously amended multiple times as further described below, and which, among other things, extended the maturity of the note to the earlier of August 1, 2026, or the occurrence of (i) a Change of Control (as defined in the amended note) or (ii) the sale of all or substantially all of the assets of R2 Technologies. The note can be repaid at any time with an optional prepayment of the entire then-outstanding and unpaid principal and accrued interest upon five-days written notice to Lancer Capital. The amended note has an interest rate of 12% and removed certain exit and default fees. Accrued and unpaid interest is capitalized monthly into the principal balance. As of September 30, 2025, the effective interest rate on the note, as amended, was 17.0%.

The total new initial principal amount of the amended Lancer Note on August 4, 2025 was $43.5 million, which incorporated the $20.0 million principal amount of the note as previously amended effective January 31, 2024 (which was comprised of a principal amount of $17.4 million and unpaid accrued interest of $2.6 million), accrued interest of $7.0 million and $16.5 million in accrued exit fees which had been incurred from January 31, 2024 through August 4, 2025. In addition, a new 5% extension fee of $2.2 million was capitalized into the principal amount on August 4, 2025.

As of September 30, 2025, the total carrying amount relating to the note, which is included within the Current portion of debt obligations in the Condensed Consolidated Balance Sheet, was $44.6 million, inclusive of $46.5 million of principal (which includes capitalized interest and fees), partially offset by $1.9 million of the unamortized OID for the extension fee. Interest expense, including amortization of fees, related to the Lancer Note was $3.1 million and $12.8 million for the three and nine months ended September 30, 2025, respectively.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

On February 20, 2025, Pansend closed on a $3.5 million intercompany convertible 13.0% note instrument with R2 Technologies. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend into shares of a new Series E Convertible Preferred Stock ("Series E") in R2 Technologies upon written notice to R2 Technologies and has a maturity date, as amended on July 23, 2025, of the earlier of July 31, 2026, or a change in control of R2 Technologies, as defined in the note. On June 9, 2025, Pansend closed on a $3.0 million intercompany convertible 13.0% note instrument with R2 Technologies, of which $2.5 million had been funded as of September 30, 2025. The principal amount of the note, together with any interest then accrued and unpaid, is convertible at the option of Pansend into shares of a new Series F Convertible Preferred Stock ("Series F") in R2 Technologies upon written notice to R2 Technologies and has a maturity date, as amended on July 23, 2025, of the earlier of July 31, 2026, or a change in control of R2 Technologies, as defined in the note. These notes and related intercompany interest are eliminated on consolidation. Subsequent to quarter end, in October and November 2025, an additional $0.5 million was funded.

Refer to Note 15. Equity and Temporary Equity to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information on R2 Technologies' convertible preferred stock and convertible notes.

### Spectrum

On August 4, 2025, Spectrum entered into a Tenth Omnibus Amendment to Secured Notes and Limited Consent to MSD Secured Note and Intercreditor Agreement with the note holders of Spectrum’s $69.7 million 8.50% and 11.45% Notes (the “Spectrum Notes”) to, among other things, extend the maturity of such notes from August 15, 2025 to September 30, 2026 (the “Spectrum Notes Extension”). As a result of the Spectrum Notes Extension, additional exit fees of $9.9 million were incurred, and the total exit fees of $25.8 million are reflected within Accrued liabilities in the Condensed Consolidated Balance Sheet as of September 30, 2025, and are payable on the earlier of maturity or repayment of the principal, were recorded as original issue discount and are being amortized over the remaining life of the notes, which is assumed to be the maturity date.

Interest is capitalized and payable upon maturity of the notes. As of September 30, 2025 and December 31, 2024, the weighted-average effective interest rates on the notes, as amended, were 25.0% and 22.8%, respectively.

In connection with the Spectrum Notes Extension, INNOVATE entered into a related side letter (the "Spectrum Letter") with the lenders, which requires us to meet certain milestones with respect to strategic alternatives for the Spectrum segment, such that, if the Spectrum Notes are not repaid in full in cash on or before November 1, 2025, we will be required to commence an alternative strategic process for HC2B. As of November 1, 2025, the Spectrum Notes had not been repaid and we have initiated a strategic process for HC2B, and are in compliance with the milestone covenants requirements.

The Spectrum Letter also requires us to utilize proceeds from a sale of certain of its existing operations, as allowable under the Company's current agreements and indentures and after all other required payments have been made, for repayment of a portion of Broadcasting's Senior Secured Notes. Assuming there are sufficient proceeds remaining after such repayment, we will be required to purchase the institutional investors' equity interests in HC2B and DTV for an aggregate purchase price of $2.0 million. The lenders hold 20,408 shares of common stock in HC2B 2,222,222 shares of common stock in DTV, and warrants to purchase 145,825 shares of common stock of HC2B which can be exercised at any time until August 31, 2028, at an exercise price of $0.01 per share.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference for additional information.

### Restrictive Covenants

Pursuant to the 8.50% 2026 Senior Secured Notes Supplemental Indenture, substantially all of the restrictive covenants for the 8.50% 2026 Senior Secured Notes were eliminated.

The indenture governing the 2027 Senior Secured Notes dated August 4, 2025, by and among INNOVATE, the guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee (in such capacity, the “10.50% 2027 Senior Secured Notes Trustee”) and collateral trustee (the "10.50% 2027 Senior Secured Notes Indenture"), contains certain affirmative and negative covenants limiting, among other things, the ability of the Company, and, in certain cases, the Company’s subsidiaries, to incur additional indebtedness; create liens; pay dividends or make distributions in respect of capital stock; make certain restricted payments; sell assets; engage in certain transactions with affiliates; or consolidate or merge with, or sell substantially all of its assets to, another person. Additionally, the 10.50% 2027 Senior Secured Notes Indenture requires the Company to meet certain milestones with respect to strategic alternatives for our operating subsidiaries, including asset sales generating at least $150 million in net proceeds, such that by September 1, 2025 the Company has a bona fide bid or term sheet related to a potential sale, a fully executed purchase or equity agreement by November 1, 2025, and an executed transaction with applied proceeds to the 10.50% 2027 Senior Secured Notes Indenture no later than February 1, 2026. In the event the milestones are not reached, the Company will be required to commence a sales process for DBMG. These covenants are subject to a number of important exceptions and qualifications. As of September 30, 2025, the September 1, 2025 milestone was not reached and we have thus initiated a sales process for DBMG, and we are in compliance with the milestone covenants requirements.

In connection with the August 2025 Spectrum Notes Extension, INNOVATE entered into a related side letter (the "Spectrum Letter") with the lenders, which requires the Company to meet certain milestones with respect to strategic alternatives for the Spectrum segment, such that, if the Spectrum Notes are not repaid in full in cash on or before November 1, 2025, we will be required to commence an alternative strategic process for the Spectrum segment. As of November 1, 2025, the Spectrum Notes had not been repaid and we have initiated a strategic process for HC2B, and are in compliance with the milestone covenants requirements.

The instruments governing the Company’s Series A-3 Preferred Stock and Series A-4 Preferred Stock also limit our and our subsidiaries ability to take certain actions, including, among other things, to incur additional indebtedness; issue additional Series A-3 Preferred Stock and Series A-4 Preferred Stock; engage in transactions with affiliates; and make certain restricted payments. These limitations are subject to a number of important exceptions and qualifications.

We have conducted our operations in a manner that has resulted in compliance with the indentures, and as of September 30, 2025, we were in compliance with the covenants of our debt agreements. The September 1, 2025 milestone was not reached on our 2027 Senior Secured Notes, the Company has thus initiated a sales process for DBMG, and is in compliance with the milestone covenants requirement. Due to other pending milestones which will require the sale of assets and use of proceeds to pay off our debt, we have classified our debt as current. If we fail to meet these pending milestones, and therefore are unable to remain in compliance and do not make alternate arrangements or obtain a waiver, an event of default would occur under our indentures which, among other remedies, could result in the outstanding obligations under the indenture becoming immediately due and payable and permitting the exercise of remedies with respect to the collateral. There is no assurance that we will be able to complete any non-operational transaction we may undertake to maintain compliance with covenants or, even if we complete any such transaction, that we will be able to maintain compliance for any subsequent period.

The debt associated with our Infrastructure segment contain customary restrictive and financial covenants related to debt levels and performance, including a Fixed Charge Coverage Ratio covenant, and a Senior Funded Indebtedness to EBITDA Ratio, both as defined in the agreement. As of September 30, 2025, our Infrastructure segment was in compliance with the covenants of its debt agreement.

Refer to Note 11. Debt Obligations to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference, for additional information.

### Short- and Long-Term Liquidity Considerations and Risks

Our Non-Operating Corporate segment's liquidity needs have primarily been for interest payments on our senior secured notes, convertible notes, Revolving Line of Credit, CGIC Note, and dividend payments, out of legally available funds, on our Series A-3 and Series A-4 Preferred Stock and recurring operational expenses. As a result of our recent refinancing as discussed in "*Indebtedness*" above, certain interest payments for our Corporate debt will be paid in kind and therefore will be incorporated into the respective principal balances to be paid on maturity of the respective debt.

On a consolidated basis, as of September 30, 2025, we had $35.5 million of cash and cash equivalents, excluding restricted cash, compared to $48.8 million as of December 31, 2024. On a stand-alone basis, as of September 30, 2025, our Non-Operating Corporate segment had cash and cash equivalents, excluding restricted cash, of $1.9 million and no marketable securities, as compared to cash and cash equivalents, excluding restricted cash, of $13.8 million and $1.8 million of marketable securities as of December 31, 2024.

Our subsidiaries' principal liquidity requirements arise from cash used in operating activities, debt service, and capital expenditures, including purchases of steel construction equipment, OTA broadcast station equipment, development of back-office systems, operating costs and expenses, and income taxes.

As of September 30, 2025, we had $700.4 million of principal indebtedness on a consolidated basis compared to $668.3 million as of December 31, 2024, a net increase of $32.1 million, due to an increase in debt at our Non-Operating Corporate and Life Sciences segments from the recent third quarter refinancing transactions, partially offset by a decrease in debt at our Infrastructure segment due to their second quarter 2025 refinancing transaction and repayments on their debt. The increase at our Non-Operating Corporate segment was due to the August 2025 exchanges of our senior secured notes and convertible notes and the capitalization of fees and unpaid accrued interest into the principal amounts of the new notes, the capitalization of extension fees and unpaid accrued interest into the principal amount of our CGIC note, the exchange of the accrued value of 8,063 shares of Series A-4 Preferred Stock of the Company held by CGIC, and unpaid accrued dividends for the A-3 and A-4 Preferred Stock for an additional principal amount of the CGIC Note. The increase at our Life Sciences segment was due to the capitalization of fees and $22.5 million of unpaid accrued interest at R2 Technologies into the outstanding principal balance of their note with Lancer. The increases in debt were partially offset by a $40.6 million decrease in debt at our Infrastructure segment due to their second quarter 2025 refinancing transaction and repayments on their debt.

On a stand-alone basis, our Non-Operating Corporate segment principal indebtedness was $480.1 million and $429.9 million as of September 30, 2025 and December 31, 2024, respectively. The September 30, 2025 indebtedness balance consists of the $360.4 million aggregate principal amount of new 10.50% 2027 Senior Secured Notes, $53.5 million aggregate principal amount of new 9.50% 2027 Convertible Notes, $1.9 million aggregate principal amount remaining of 8.50% 2026 Senior Secured Notes, $0.2 million aggregate principal amount remaining of 7.50% 2026 Convertible Notes, $44.1 million principal amount of the CGIC Note and $20.0 million aggregate principal amount drawn on our Revolving Line of Credit.

Our Non-Operating Corporate segment is required to make semi-annual interest payments on the 10.50% 2027 Senior Secured Notes and on the 2027 Convertible Notes, on February 1st and August 1st of each year. For the first interest period only, which is the interest period ending on January 31, 2026, interest will be paid in kind. Interest payments on the CGIC Note are required on a monthly basis; however, interest will be paid in kind through August 31, 2026. All remaining interest payments will be paid in cash in arrears. We are also required to make quarterly interest payments on our Revolving Line of Credit and semi-annual interest payments on the 8.50% 2026 Senior Secured Notes and 2026 Convertible Notes on February 1st and August 1st of each year.

We are required to make dividend payments, out of legally available funds, on our outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock on January 15th, April 15th, July 15th, and October 15th of each year. The Series A-3 and Series A-4 Preferred Stock accrue a cumulative quarterly cash dividend at an annualized rate of 7.50%. The accrued values of the Series A-3 and Series A-4 Preferred Stock accrete quarterly at an annualized rate of 4.00% that is reduced to 2.00% or 0.0% if the Company achieves specified rates of growth measured by increases in its net asset value; provided, that the accreting dividend rate will be 7.25% in the event that (A) the daily volume weighted-average price ("VWAP") of the Company's common stock is less than a certain threshold amount, (B) the Company's common stock is not registered under Section 12(b) of the Securities Exchange Act of 1934, as amended, and (C) the Company's common stock is not listed on certain national securities exchanges or the Company is delinquent in the payment of any cash dividends.

During the first quarter of 2025, the Company accrued the 7.5% quarterly dividend of $0.3 million and subsequently paid the dividend in April 2025. During the second and third quarters of 2025, INNOVATE's Board of Directors (the "Board") did not declare any cash dividends with respect to INNOVATE’s issued and outstanding Series A-3 Preferred Stock and Series A-4 Preferred Stock. Aggregate quarterly dividends of $0.7 million and $0.5 million for the second and third quarters of 2025, respectively, included the annual cash dividend of 7.5% per annum which was accrued and also the accreting dividend of 7.25% per annum. In addition, during the second quarter of 2025, the Company recorded accretion and accrual of additional dividends of $1.3 million related to prior years, and $0.2 million related to the first quarter of 2025. On August 4, 2025, $0.5 million in accrued quarterly dividends was exchanged for an additional principal amount of the CGIC note as part of the Preferred Stock Exchange. Refer to Note 11. Debt Obligations and Note 15. Equity and Temporary Equity for additional information.

Our Non-Operating Corporate segment received $0.1 million and $15.9 million in net tax sharing payments from our Infrastructure segment for the three and nine months ended September 30, 2025, respectively. Additionally, our Non-Operating Corporate segment received $4.0 million and $9.0 million in dividends from our Infrastructure segment during the three and nine months ended September 30, 2025, respectively. Subsequent to quarter end, DBMG declared a $8.8 million cash dividend which was paid on November 10, 2025, of which INNOVATE received approximately $8.0 million.

We have financed our growth and operations to date, and expect to finance our future growth and operations, through public offerings and private placements of debt and equity securities, credit facilities, vendor financing, finance lease financing and other financing arrangements, as well as cash generated from the operations of our subsidiaries. In the future, we may also choose to sell assets or certain investments to generate cash. We are currently exploring strategic alternatives and it is anticipated that within the next twelve months we will generate cash proceeds from an asset sale that will be used to repay certain debt obligations as required.

### 2024 Rights Offering and Concurrent Private Placement

On March 8, 2024, the Company commenced a rights offering ("Rights Offering"), in which each holder of the Company’s common stock, Series A-3 Convertible Participating Preferred Stock, Series A-4 Convertible Participating Preferred Stock and the 2026 Convertible Notes as of March 6, 2024 (the “rights offering record date”), were granted rights to purchase common stock. In connection with the Rights Offering, the Company entered into an Investment Agreement with Lancer Capital (the "Investment Agreement"), pursuant to which Lancer Capital agreed to purchase up to $19.0 million of Series C Preferred Stock as a backstop to the Rights Offering (the "Backstop Commitment") and to purchase $16.0 million of Series C Preferred Stock in a private placement transaction ("Concurrent Private Placement"). Lancer Capital is an investment fund led by Avram A. Glazer, the Chairman of the Board and the Company’s largest stockholder. As the Rights Offering had not yet settled by March 28, 2024, in accordance with the Investment Agreement, Lancer Capital purchased $25.0 million of Series C Preferred Stock, referred to as the "equity advance." On April 24, 2024, the Company completed and closed on the Rights Offering and issued a total of 530,611 shares of common stock for $3.7 million. In addition, Lancer Capital purchased an additional approximately 6,286 Series C Preferred Stock for $6.3 million under the Backstop Commitment. In total, the Company received $35.0 million in aggregate gross proceeds related to the Rights Offering and Concurrent Private Placement and incurred $1.8 million in dealer manager fees and other related costs which were capitalized into Additional paid in capital ("APIC"). On June 18, 2024, the Company's shareholders approved the conversion of the Series C Preferred Stock into common stock, and approximately 31,286 shares of Series C Preferred Stock, which were held by Lancer Capital, were converted into 4,469,390 shares of common stock, and there were no shares of the Series C Preferred Stock outstanding subsequent to their conversion into the Company's common stock.

INNOVATE utilized the net proceeds from the Rights Offering and Concurrent Private Placement for general corporate purposes, including debt service and for working capital. As a result of the closing of the Rights Offering and Concurrent Private Placement, a mandatory prepayment was required on the CGIC Note, and on April 26, 2024, INNOVATE redeemed $4.1 million of the CGIC Note. Refer to Note 11. Debt Obligations for additional information.

### Going Concern

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming that the Company will continue as a going concern. However, as of the date of these financial statements, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

The principal conditions leading to this conclusion are the upcoming maturities of certain Corporate debt, Spectrum's debt and R2 Technologies' debt and from certain cross-default provisions in our 2027 Senior Secured Notes. Based on these conditions, we may not be able to meet our obligations at maturity and comply with certain cross-default provisions under the 2027 Senior Secured Notes over the next twelve months, including from any potential breach of the milestone covenant under Section 4.27(b) of the 2027 Senior Secured Notes Indenture.

Management has evaluated the significance of these conditions in relation to the Company's ability to meet its obligations. The potential inability to refinance or extend the maturity of the aforementioned current debt, or to obtain additional financing, raises substantial doubt about the Company's ability to continue as a going concern.

Management plans to alleviate these conditions through various initiatives it is currently exploring, including pursuing asset sales and raising additional capital. However, there can be no assurance that we will have the ability to raise additional capital when needed, be successful in any asset sales, or refinance our existing debt, on attractive terms, or at all nor any assurances that lenders will provide additional extensions, waivers or amendments in the event of future non-compliance with our debt covenants or other possible events of default. Further, there can be no assurance that we will be able to execute a reduction, extension, or refinancing of the debt, or that the terms of any replacement financing would be as favorable as the terms of the debt prior to the maturity date. There can be no assurance that these plans will be successfully implemented or that they will mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern.

The unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q do not include any adjustments to the carrying amounts and classification of assets, liabilities, or expenses that may result if the Company is unable to continue as a going concern.

While we have noted the conditions above regarding our ability to continue as a going concern, it is important to note that our largest subsidiary, DBMG, is operationally profitable, continues to maintain a strong financial position and remains in good standing with its lenders. Under INNOVATE’s Senior Secured Notes Indenture, DBMG is a restricted subsidiary, not a guarantor, and INNOVATE’s equity interests in DBMG are pledged as collateral.

### Capital Expenditures

Capital expenditures are set forth in the table below (in millions):

|  | Three Months Ended September 30, 2025 | 2024 | Nine Months Ended September 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Infrastructure | $7.0 | $2.8 | $16.2 | $10.7 |
| Life Sciences | — | — | — | 0.1 |
| Spectrum | 0.8 | 0.3 | 2.4 | 1.0 |
| Total | $7.8 | $3.1 | $18.6 | $11.8 |

### Summary of Consolidated Cash Flows

The below table summarizes the cash provided by or used in our activities (in millions):

|  | Nine Months Ended September 30, 2025 | 2024 | Change |
| --- | ---: | ---: | ---: |
| Cash provided by (used in) operating activities | $45.5 | $(32.3) | $77.8 |
| Cash used in investing activities | (15.1) | (4.0) | (11.1) |
| Cash (used in) provided by financing activities | (44.1) | 6.4 | (50.5) |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | 0.5 | 0.1 | 0.4 |
| Net decrease in cash and cash equivalents, including restricted cash | $(13.2) | $(29.8) | $16.6 |

#### Operating Activities

Cash provided by operating activities was $45.5 million for the nine months ended September 30, 2025, as compared to cash used in operating activities of $32.3 million for the nine months ended September 30, 2024, an improvement of $77.8 million. Cash flows from operations are primarily influenced by changes in the timing of demand for services and by operating margins, but can also be affected by working capital needs associated with our operations. For the nine months ended September 30, 2025, the improvement in cash flows from operating activities was primarily driven by an increase in cash provided by operating activities at our Infrastructure segment and a decrease in cash used in operating activities at our Non-Operating Corporate segments. The improvement at our Infrastructure segment was due to an increase in working capital inflows primarily due to normal business fluctuations in accounts receivable, contract-related assets and liabilities, accounts payable, and other accrued liabilities due to the timing of regular billing and collection activities and ordinary project activity. Our Non-Operating Corporate segment's decrease in cash used in operating activities was primarily due to a decrease in cash paid for interest, partially offset by an increase in cash paid for taxes, and an increase in operating expenses primarily due to refinancing costs.

#### Investing Activities

Cash used in investing activities was $15.1 million for the nine months ended September 30, 2025, as compared to $4.0 million for the nine months ended September 30, 2024, an increase in cash used in investing activities of $11.1 million. Capital expenditures totaled $18.6 million, or $17.2 million net of proceeds from disposals, for the nine months ended September 30, 2025, as compared to $11.8 million, or $1.9 million net proceeds after disposals, for the nine months ended September 30, 2024, for a net increase in cash used in investing activities of $15.3 million. The increase was primarily driven by our Infrastructure segment, which had more PP&E sales in the comparable period due to a plant closure in the first quarter of 2024, and increased PP&E additions in the current period at our Infrastructure and Spectrum segments. In addition, during the nine months ended September 30, 2025, our Spectrum segment had an increase in acquisition payments of $0.2 million and our Non-Operating Corporate segment purchased marketable investments for $0.3 million, while the comparable period included unrepeated proceeds of $0.5 million in other investing activities related to a note receivable at our Life Sciences segment. These increases in cash used in investing activities were partially offset by the sale of marketable securities at our Non-Operating Corporate segment for total proceeds of $2.9 million in the current period and unrepeated loans made by our Life Sciences segment to MediBeacon of $2.3 million in the comparable period.

#### Financing Activities

Cash used in financing activities was $44.1 million for the nine months ended September 30, 2025, as compared to cash provided by financing activities of $6.4 million for the nine months ended September 30, 2024, an increase in cash used in financing activities of $50.5 million. The increase in financing cash outflows was primarily driven by our Non-Operating Corporate segment, which received $33.2 million in net proceeds from the Rights Offering and Concurrent Private Placement in 2024. In addition, for the nine months ended September 30, 2025, net repayments on other debt obligations totaled $16.5 million, as compared to net repayments of $0.9 million in the comparable period, an increase in cash outflows of $15.6 million. The increase in net repayments on other debt obligations was primarily driven by our Infrastructure segment, who refinanced their debt in the current period, and had a $20.7 million net increase in other debt obligation outflows, primarily from term loan activity. This was partially offset by our Non-Operating Corporate segment, due to an unrepeated $4.1 million repayment on the CGIC Note in the comparable period and unrepeated $1.0 million payment for partial redemption of our 2026 Convertible Notes in the comparable period. Net cash outflows from revolving credit facility activity were $25.9 million for nine months ended September 30, 2025, as compared to $25.0 million for the nine months ended September 30, 2024, for an increase in net cash outflows of $0.9 million, which was attributable to our Infrastructure segment. The increase in cash used in financing activities was also driven by a $0.6 million increase in dividends paid primarily due to dividends declared and paid by DBMG during the nine months ended September 30, 2025 and a $0.2 million increase in cash paid for other financing activities.

### Infrastructure

#### Cash Flows

Cash flows from operating activities are the principal source of cash used to fund DBMG’s operating expenses, interest payments on debt, and capital expenditures. DBMG's short-term cash needs are primarily for working capital to support operations including receivables, inventories, and other costs incurred in performing on its contracts. DBMG attempts to structure the payment arrangements under its contracts to match costs incurred under the project. To the extent it is able to bill in advance of costs incurred, DBMG generates working capital through billings in excess of costs and recognized earnings on uncompleted contracts. DBMG relies on its credit facilities to meet its working capital needs. DBMG believes that its available funds, cash generated by operating activities and funds available under its bank credit facilities will be adequate to meet all funding requirements for its operating expenses, working capital needs, interest payments on debt and capital expenditures for the foreseeable future. However, DBMG may expand its operations through future acquisitions and may require additional equity or debt financing.

DBMG is required to make monthly interest payments on all of its debt. Based upon the September 30, 2025, debt balance, DBMG anticipates that its interest payments will be approximately $2.0 million for the fourth quarter of 2025.

### New Accounting Pronouncements

For information on new accounting pronouncements, refer to Note 2. Summary of Significant Accounting Policies to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Critical Accounting Estimates

There have been no material changes in the Company’s critical accounting policies during the period ended September 30, 2025. For information about critical accounting policies and estimates, refer to “Critical Accounting Estimates” under Item 7 of our 2024 Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025.

### Related Party Transactions

For a discussion of our Related Party Transactions, refer to Note 16. Related Parties to the Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

### Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains or incorporates a number of "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based on current expectations, and are not strictly historical statements. In some cases, you can identify forward-looking statements by terminology such as "if," "may," "should," "believe," "anticipate," "future," "forward," "potential," "estimate," "opportunity," "goal," "objective," "growth," "outcome," "could," "expect," "intend," "plan," "strategy," "provide," "commitment," "result," "seek," "pursue," "ongoing," "include" or in the negative of such terms or comparable terminology. These forward-looking statements inherently involve certain risks and uncertainties and are not guarantees of performance, results, or the creation of stockholder value, although they are based on our current plans or assessments which we believe to be reasonable as of the date hereof.

Factors that could cause actual results, events and developments to differ include, without limitation: the ability of our subsidiaries (including, target businesses following their acquisition) to generate sufficient net income and cash flows to make upstream cash distributions, capital market conditions, our and our subsidiaries’ ability to identify any suitable future acquisition opportunities, efficiencies/cost avoidance, cost savings, income and margins, growth, economies of scale, combined operations, future economic performance, conditions to, and the timetable for, completing future acquisitions and dispositions and the successful integration of acquisitions, litigation, potential and contingent liabilities, management’s plans, changes in regulations and taxes.

We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

Forward-looking statements are not guarantees of performance. You should understand that the following important factors, in addition to those discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025, and the documents incorporated herein by reference, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements. You should also understand that many factors described under one heading below may apply to more than one section in which we have grouped them for the purpose of this presentation. As a result, you should consider all of the following factors, together with all of the other information presented herein, in evaluating our business and that of our subsidiaries.

### INNOVATE Corp. and Subsidiaries

Our actual results or other outcomes may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our dependence on distributions from our subsidiaries to fund our operations and payments on our obligations;
- substantial doubt about our ability to continue operating as a going concern;
- our possible inability to refinance our existing debt, on attractive terms, or at all, or raise additional capital when needed;
- the impact on our business and financial condition of our substantial indebtedness and the significant additional indebtedness and other financing obligations we may incur;
- the impact of covenants in the Indentures governing INNOVATE’s 2027 Senior Secured Notes, 2027 Convertible Notes, 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Subordinated Secured Promissory Note and Revolving Line of Credit, the Certificates of Designation governing INNOVATE’s Series A-3 Preferred Stock and Series A-4 Preferred Stock and all other subsidiary debt obligations as summarized in Note 11. Debt Obligations to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC March 31, 2025, and any future amendments or other new financing agreements on our ability to operate our business and finance our pursuit of acquisition opportunities;
- our possible inability to generate sufficient liquidity, margins, earnings per share, cash flow and working capital from our operating segments;
- our dependence on certain key personnel including the passing in 2023 of Mr. Barr, our former CEO, President and Director and the successful transition of his management responsibilities;
- bank failures or other similar events that could adversely affect our and our customers' and vendors' liquidity and financial performance;
- our possible inability to hire and retain qualified executive management, sales, technical and other personnel;
- the potential for, and our ability to, remediate future material weaknesses in our internal controls over financial reporting;
- changes in market conditions, including from political regulatory or market uncertainty, changes in foreign exchange rates, interest rates or inflation, supply chain disruptions, labor shortages and increases in overall price levels, including in transportation costs;
- the uncertain effects of U.S. and foreign government actions affecting international trade and economic policy, including changes in volatility in tariffs and trade policies and retaliatory actions, on credit markets, customers, and customer retention, and demand for our products and services;
- increased competition in the markets in which our operating segments conduct their businesses;
- limitations on our ability to successfully identify any strategic acquisitions or business opportunities and to compete for these opportunities with others who have greater resources;
- our ability to effectively increase the size of our organization, if needed, and manage our growth;
- the impact of expending significant resources in considering acquisition targets or business opportunities that are not consummated;
- our expectations and timing with respect to our ordinary course acquisition activity and whether such acquisitions are accretive or dilutive to stockholders;
- the effect any interests our officers, directors, stockholders and their respective affiliates may have in certain transactions in which we are involved;
- uncertain global economic conditions in the markets in which our operating segments conduct their businesses;
- the effects related to or resulting from ongoing and recent geopolitical events, such as the political unrest and military conflicts in the Middle East, Russia and Ukraine, including the imposition of additional sanctions and export controls, as well as the broader impact to financial markets and the global macroeconomic and geopolitical environment;
- the impact of catastrophic events, including natural disasters, pandemic illness and the outbreak of war, or acts of terrorism;
- potential impacts on our business resulting from climate change, greenhouse gas regulations, and the impact of climate change-related changes in the frequency and severity of weather patterns;
- the impact of additional material charges associated with our oversight of acquired or target businesses and the integration of our financial reporting;
- tax consequences associated with our acquisition, holding and disposition of target companies and assets;
- our ability to remain in compliance with the listing standards of the NYSE;
- the 2024 Reverse Stock Split may not result in a sustained increase in the per share price of our common stock;
- the ability of our operating segments to attract and retain customers;
- our expectations regarding the timing, extent and effectiveness of our cost reduction initiatives and management’s ability to moderate or control discretionary spending;
- management’s plans, goals, forecasts, expectations, guidance, objectives, strategies and timing for future operations, acquisitions, synergies, asset dispositions, fixed asset and goodwill impairment charges, tax and withholding expense, selling, general and administrative expenses, product plans, performance and results;
- management’s assessment of market factors and competitive developments, including pricing actions and regulatory rulings;
- our expectations and timing with respect to any strategic dispositions and sales of our operating subsidiaries, or businesses, that we may make in the future and the effect of any such dispositions or sales on our results of operations; and
- the possibility of indemnification claims arising out of divestitures of businesses.

### Infrastructure / DBM Global Inc.

Our actual results or other outcomes of DBMG, and, thus, our Infrastructure segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- adverse impacts from weather affecting DBMG’s performance and timeliness of completion of projects, which could lead to increased costs and affect the quality, costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- our possible inability to refinance our existing debt, on attractive terms, or at all, or raise additional capital when needed;
- cost overruns on fixed-price or similar contracts or failure to receive timely or proper payments on cost-reimbursable contracts, whether as a result of improper estimates, performance, disputes, or otherwise;
- uncertain timing and funding of new contract awards, as well as project cancellations;
- potential impediments and limitations on our ability to complete ordinary course acquisitions in anticipated time frames or at all;
- changes in the costs or availability of, or delivery schedule for, equipment, components, materials, labor or subcontractors;
- changes in economic conditions, including from the impact of inflationary pressures and changes in interest rates;
- adverse outcomes of pending claims or litigation or the possibility of new claims or litigation, and the potential effect of such claims or litigation on DBMG’s business, financial condition, results of operations or cash flow;
- risks associated with labor productivity, including performance of subcontractors that DBMG hires to complete projects;
- its ability to realize cost savings from expected performance of contracts, whether as a result of improper estimates, performance, or otherwise;
- its ability to settle or negotiate unapproved change orders and claims;
- fluctuating revenue resulting from a number of factors, including the cyclical nature of the individual markets in which our customers operate; and
- lack of necessary liquidity to provide bid, performance, advance payment and retention bonds, guarantees, or letters of credit securing DBMG’s obligations under bids and contracts or to finance expenditures prior to the receipt of payment for the performance of contracts.

### Life Sciences / Pansend Life Sciences, LLC

Our actual results or other outcomes of Pansend Life Sciences, LLC, and, thus, our Life Sciences segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our Life Sciences segment's possible inability to refinance its existing debt, on attractive terms, or at all, or raise additional capital when needed;
- our Life Sciences segment’s ability to invest in development stage companies;
- our Life Sciences segment’s ability to develop products and treatments related to its portfolio companies;
- medical advances in healthcare and biotechnology; and
- governmental regulation in the healthcare industry.

### Spectrum / HC2 Broadcasting Holdings Inc.

Our actual results or other outcomes of Broadcasting, and, thus, our Spectrum segment, may differ from those expressed or implied by forward-looking statements contained herein due to a variety of important factors, including, without limitation, the following:

- our Spectrum segment's possible inability to refinance its existing debt, on attractive terms, or at all, or raise additional capital when needed;
- our Spectrum segment’s ability to operate in highly competitive markets and maintain market share;
- our Spectrum segment’s ability to effectively implement its business strategy or be successful in the operation of its business;
- new and growing sources of competition in the broadcasting industry; and
- FCC regulation of the television broadcasting industry.

We caution the reader that undue reliance should not be placed on any forward-looking statements, which speak only as of the date of this document. Neither we nor any of our subsidiaries undertake any duty or responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this document or to reflect actual outcomes, except as required by applicable law.

## Controls and procedures

As filed, 1,629 characters.

### Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended (the "Exchange Act") as of the end of the period covered by this report. Based on this evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2025, our disclosure controls and procedures were effective. Disclosure controls and procedures mean our controls and other procedures that are designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 4,555 characters.

Reference is made to the factors set forth under the caption “Special Note Regarding Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our Annual Report, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our Annual Report and our Quarterly Report, except as set forth below.

***The agreements governing our indebtedness, including the indentures governing INNOVATE’s 2027 Senior Secured Notes, 2027 Convertible Notes, 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Subordinated Secured Promissory Note and Revolving Line of Credit, and the Certificates of Designation with respect to our Series A-3 and Series A-4 Preferred Stock, contain various covenants that limit our discretion in the operation of our business and/or require us to meet financial maintenance tests and other covenants. The failure to comply with such tests and covenants could have a material adverse effect on us.***

The agreements governing our indebtedness, including the indentures governing INNOVATE’s 2027 Senior Secured Notes, 2027 Convertible Notes, 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Subordinated Secured Promissory Note and Revolving Line of Credit, and the Certificates of Designation with respect to our Series A-3 and Series A-4 Preferred Stock, contain, and any of our other future financing agreements may contain, covenants imposing operating and financial restrictions on our businesses.

The indentures governing INNOVATE’s 2027 Senior Secured Notes, 2027 Convertible Notes, 2026 Senior Secured Notes, 2026 Convertible Notes, CGIC Subordinated Secured Promissory Note and Revolving Line of Credit, and the Certificates of Designation with respect to our Series A-3 and Series A-4 Preferred Stock contain, and any future debt agreements may contain, various covenants, including those that restrict our ability to, among other things:

- incur liens on our property, assets and revenue;
- borrow money, and guarantee or provide other support for the indebtedness of third parties;
- redeem or repurchase our capital stock;
- make scheduled interest and principal or other payments or prepay, redeem or repurchase, certain of our indebtedness, including Existing Notes that did not participate in the Exchange Offer and the Solicitation or our Series A-3 and Series A-4 preferred stock;
- enter into certain change of control transactions;
- make investments in entities that we do not control, including joint ventures;
- enter into certain asset sale transactions, including divestiture of certain company assets and divestiture of capital stock of wholly-owned subsidiaries;
- enter into certain transactions with affiliates; and
- enter into secured financing arrangements.

The debt facilities at our subsidiaries contain similar covenants applicable to each respective subsidiary. These covenants may limit our ability to effectively operate our businesses. For example, DBMG has an indemnity agreement with its surety bond provider that also contains covenants on retention of capital and working capital requirements for DBMG, which may limit the amount of dividends DBMG may pay to its stockholders.

The indentures governing INNOVATE’s 2027 Senior Secured Notes and 2027 Convertible Notes also require us to meet certain milestones with respect to strategic alternatives for our operating subsidiaries, including asset sales generating at least $150 million in net proceeds.

Any failure to comply with the restrictions in the indentures governing INNOVATE’s 2027 Senior Secured Notes and 2027 Convertible Notes, or any other agreement governing our existing indebtedness or indebtedness we may incur in the future, may result in an event of default under those agreements. Such default may allow the creditors to accelerate the related debt, which acceleration may trigger cross-acceleration or cross-default provisions in other debt. If any of these risks were to occur, our business and operations could be materially and adversely affected.

The Certificates of Designation provide the holders of our Series A-3 and Series A-4 Preferred Stock with consent and voting rights with respect to certain of the matters referred to above, in addition to certain corporate governance rights. These restrictions may interfere with our ability to obtain financings or to engage in other business activities, which could have a material adverse effect on our business and operations.

Filed Nov 12, 2025.
Source: SEC EDGAR, the filing index for accession 0001006837-25-000127. Last ingested by Listed: Nov 14, 2026, 23:42 ET. No prices; not investment advice.
